A    O
group    O
of    O
fructan    B-Polysaccharide114994004
produced    O
by    O
bacteria    O
or    O
created    O
by    O
breaking    O
down    O
other    O
kinds    O
of    O
plant    O
fructans    O
,    O
called    O
levan    B-Polysaccharide114994004
beta    I-Polysaccharide114994004
2→6    I-Polysaccharide114994004

He    O
worked    O
on    O
connective    O
tissue    O
and    O
determined    O
the    O
properties    O
of    O
hyaluronan    B-Polysaccharide114994004
in    O
the    O
1930s    O
.    O

He    O
then    O
moved    O
to    O
New    O
York    O
and    O
worked    O
at    O
the    O
Columbia    O
University    O
doing    O
research    O
on    O
hyaluronan    B-Polysaccharide114994004
.    O

The    O
nucleus    O
pulposus    O
consists    O
of    O
large    O
vacuolated    O
notochord    O
cells    O
,    O
small    O
chondrocyte    O
-    O
like    O
cells    O
,    O
collagen    O
fibrils    O
,    O
and    O
aggrecan    O
,    O
a    O
proteoglycan    B-Polysaccharide114994004
that    O
aggregates    O
by    O
binding    O
to    O
hyaluronan    B-Polysaccharide114994004
.    O

Other    O
molecules    O
that    O
have    O
the    O
potential    O
to    O
promote    O
nerve    O
repair    O
are    O
:    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
,    O
fibrinogen    O
,    O
fibrin    O
gels    O
,    O
self    O
-    O
assembling    O
peptide    O
scaffolds    O
,    O
alginate    O
,    O
agarose    B-Polysaccharide114994004
,    O
and    O
chitosan    B-Polysaccharide114994004
.    O

The    O
N    O
-    O
terminal    O
(    O
G1    O
)    O
globular    O
domain    O
consists    O
of    O
Ig    O
-    O
like    O
loop    O
and    O
two    O
link    O
modules    O
,    O
and    O
has    O
Hyaluronan    B-Polysaccharide114994004
(    O
HA    O
)    O
binding    O
properties    O
.    O

Other    O
medications    O
have    O
been    O
shown    O
to    O
be    O
useful    O
in    O
topical    O
treatment    O
of    O
refractory    O
ulcers    O
,    O
including    O
glycosaminoglycan    B-Polysaccharide114994004
such    O
as    O
sodium    B-Polysaccharide114994004
hyaluronate    I-Polysaccharide114994004
and    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
aminocaproic    O
acid    O
,    O
and    O
acetylcysteine    O
.    O

Hyaluronan    B-Polysaccharide114994004
is    O
a    O
glycosaminoglycan    O
polymer    O
critical    O
for    O
maintaining    O
extracellular    O
matrix    O
integrity    O
and    O
modulating    O
cell    O
-    O
cell    O
interactions    O
.    O

There    O
is    O
no    O
evidence    O
of    O
benefit    O
in    O
terms    O
of    O
live    O
birth    O
rate    O
of    O
using    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
as    O
adherence    O
medium    O
for    O
the    O
embryo    O
.    O

A    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
,    O
such    O
as    O
Restylane    O
or    O
Juvederm    O
,    O
can    O
be    O
injected    O
to    O
the    O
cheek    O
area    O
.    O

It    O
contains    O
autocross    O
-    O
linked    O
hyaluronan    B-Polysaccharide114994004
.    O

Among    O
GAGs    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
,    O
possibly    O
in    O
combination    O
with    O
cross    O
linking    O
agents    O
(    O
e.g.    O
glutaraldehyde    O
,    O
water    O
-    O
soluble    O
carbodiimide    O
,    O
etc    O
.    O
)    O
,    O
is    O
one    O
of    O
the    O
possible    O
choices    O
as    O
scaffold    O
material    O
.    O

This    O
fluid    O
is    O
rich    O
in    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
,    O
which    O
are    O
being    O
recently    O
used    O
in    O
a    O
modified    O
ICSI    O
called    O
physiological    O
ICSI    O
(    O
PICSI    O
)    O
.    O

Carbohydrates    O
–    O
ranging    O
from    O
monosaccharides    O
to    O
polysaccharides    O
and    O
including    O
blood    O
group    O
antigens    O
,    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
oligomers    O
and    O
sialic    O
acid    O
residues    O

Trehalose    O
has    O
been    O
combined    O
with    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
to    O
create    O
a    O
novel    O
artificial    O
tear    O
(    O
Thealoz    O
Duo    O
)    O
to    O
treat    O
dry    O
eye    O
.    O

Mucification    O
is    O
the    O
secretion    O
of    O
a    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
-    O
rich    O
cocktail    O
that    O
disperses    O
and    O
gathers    O
the    O
cumulus    O
cell    O
network    O
in    O
a    O
sticky    O
matrix    O
around    O
the    O
ovum    O
.    O

Synvisc    B-Polysaccharide114994004

Treatment    O
may    O
involve    O
injection    O
of    O
corticosteroids    O
or    O
hyaluronan    B-Polysaccharide114994004
into    O
the    O
joint    O
and    O
some    O
cases    O
may    O
require    O
arthroscopic    O
surgery    O
.    O

Other    O
joint    O
medications    O
,    O
like    O
"    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
"    O
and    O
"    O
Adequan    O
"    O
,    O
may    O
help    O
alleviate    O
the    O
pain    O
if    O
the    O
horse    O
has    O
mild    O
bone    O
spavin    O
.    O

Another    O
major    O
component    O
of    O
the    O
ECM    O
is    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
(    O
HA    O
)    O
,    O
a    O
glycosaminoglycan    O
.    O

Hyaladherins    O
,    O
also    O
known    O
as    O
hyaluronan    O
-    O
binding    O
proteins    O
,    O
are    O
proteins    O
capable    O
of    O
binding    O
to    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
.    O

19    O
June    O
–    O
Scientists    O
claim    O
that    O
"    O
cancerproof    O
"    O
laboratory    O
animals    O
,    O
such    O
as    O
naked    O
mole    O
-    O
rats    O
,    O
may    O
not    O
get    O
cancer    O
because    O
they    O
produce    O
an    O
"    O
extremely    O
high    O
-    O
molecular    O
-    O
mass    O
hyaluronan    B-Polysaccharide114994004
"    O
,    O
which    O
is    O
over    O
"    O
five    O
times    O
larger    O
"    O
than    O
that    O
in    O
cancer    O
-    O
prone    O
humans    O
and    O
cancer    O
-    O
susceptible    O
laboratory    O
animals    O
.    O

Polymeric    O
polyols    O
such    O
as    O
polydextrose    B-Polysaccharide114994004

A    O
group    O
of    O
fructan    B-Polysaccharide114994004
produced    O
by    O
bacteria    O
or    O
created    O
by    O
breaking    O
down    O
other    O
kinds    O
of    O
plant    O
fructans    O
,    O
called    O
levan    B-Polysaccharide114994004
beta    I-Polysaccharide114994004
2→6    I-Polysaccharide114994004

They    O
include    O
short    O
chain    O
oligo    O
-    O
saccharide    O
polymers    O
of    O
fructose    O
(    O
fructan    B-Polysaccharide114994004
)    O
and    O
galactooligosaccharides    O
(    O
GOS    O
,    O
stachyose    O
,    O
raffinose    O
)    O
,    O
disaccharides    O
(    O
lactose    O
)    O
,    O
monosaccharides    O
(    O
fructose    O
)    O
,    O
and    O
sugar    O
alcohols    O
(    O
polyols    O
)    O
,    O
such    O
as    O
sorbitol    O
,    O
mannitol    O
,    O
xylitol    O
and    O
maltitol    O
.    O

Recent    O
studies    O
address    O
the    O
level    O
of    O
various    O
non    O
-    O
structural    O
carbohydrates    O
(    O
NSC    O
)    O
,    O
such    O
as    O
fructan    B-Polysaccharide114994004
,    O
in    O
forages    O
.    O

Laminitis    O
has    O
many    O
causes    O
,    O
but    O
the    O
most    O
common    O
is    O
related    O
to    O
a    O
sugar    O
and    O
starch    O
overload    O
from    O
a    O
horse    O
overeating    O
certain    O
types    O
of    O
food    O
,    O
particularly    O
too    O
much    O
pasture    O
grass    O
high    O
in    O
fructan    B-Polysaccharide114994004
in    O
early    O
spring    O
and    O
late    O
fall    O
,    O
or    O
by    O
consuming    O
excessive    O
quantities    O
of    O
grain    O
.    O

idraparinux    B-Polysaccharide114994004
(    O
USAN    O
)    O

Polysaccharide    B-Polysaccharide114994004
peptide    I-Polysaccharide114994004
(    O
PSP    O
)    O
is    O
a    O
protein    O
-    O
bound    O
polysaccharide    O
extracted    O
from    O
the    O
edible    O
mushroom    O
Coriolus    O
versicolor    O
.    O

It    O
is    O
found    O
in    O
grains    O
or    O
granules    O
in    O
the    O
cell    O
's    O
cytoplasm    O
and    O
is    O
composed    O
of    O
an    O
α-linked    B-Polysaccharide114994004
glucose    O
polymer    O
with    O
a    O
degree    O
of    O
branching    O
intermediate    O
between    O
amylopectin    B-Polysaccharide114994004
and    O
glycogen    O
,    O
though    O
more    O
similar    O
to    O
the    O
former    O
.    O

The    O
TOAST    O
(    O
Trial    O
of    O
Org    B-Polysaccharide114994004
10172    I-Polysaccharide114994004
in    O
Acute    O
Stroke    O
Treatment    O
)    O
classification    O
is    O
based    O
on    O
clinical    O
symptoms    O
as    O
well    O
as    O
results    O
of    O
further    O
investigations    O
;    O
on    O
this    O
basis    O
,    O
a    O
stroke    O
is    O
classified    O
as    O
being    O
due    O
to    O
(    O
1    O
)    O
thrombosis    O
or    O
embolism    O
due    O
to    O
atherosclerosis    O
of    O
a    O
large    O
artery    O
,    O
(    O
2    O
)    O
embolism    O
of    O
cardiac    O
origin    O
,    O
(    O
3    O
)    O
occlusion    O
of    O
a    O
small    O
blood    O
vessel    O
,    O
(    O
4    O
)    O
other    O
determined    O
cause    O
,    O
(    O
5    O
)    O
undetermined    O
cause    O
(    O
two    O
possible    O
causes    O
,    O
no    O
cause    O
identified    O
,    O
or    O
incomplete    O
investigation    O
)    O
.    O

Their    O
storage    O
polysaccharide    O
is    O
chrysolaminarin    B-Polysaccharide114994004
.    O

The    O
cytoplasm    O
also    O
contains    O
chrysolaminarin    B-Polysaccharide114994004
and    O
some    O
volutin    O
.    O

Alguronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004

Cellulin    B-Polysaccharide114994004
or    O
cellulin    B-Polysaccharide114994004
granules    I-Polysaccharide114994004
are    O
a    O
type    O
of    O
polysaccharide    O
found    O
exclusively    O
within    O
the    O
oomyceteous    O
fungi    O
of    O
the    O
order    O
Leptomitales    O
.    O

SIGLEC    O
family    O
including    O
Myelin-associated    B-Polysaccharide114994004
glycoprotein    I-Polysaccharide114994004
(    O
MAG    O
,    O
SIGLEC-4    O
)    O
,    O
CD22    O
and    O
CD83    O

MAG    O
Myelin-associated    B-Polysaccharide114994004
glycoprotein    I-Polysaccharide114994004
acts    O
via    O
the    O
receptors    O
NgR2    O
,    O
GT1b    O
,    O
NgR1    O
,    O
p75    O
,    O
TROY    O
and    O
LINGO1    O
.    O

Myelin-associated    B-Polysaccharide114994004
glycoprotein    I-Polysaccharide114994004

Capsulan    B-Polysaccharide114994004
is    O
the    O
exopolysaccharide    B-Polysaccharide114994004
which    O
makes    O
up    O
the    O
thick    O
capsule    O
surrounding    O
the    O
unicellular    O
alga    O
"    O
Prasinococcus    O
capsulatus    O
"    O
.    O

Icodextrin    B-Polysaccharide114994004

Like    O
bemiparin    B-Polysaccharide114994004
,    O
semuloparin    O
is    O
classified    O
as    O
an    O
ultra    O
-    O
LMWH    O
because    O
of    O
its    O
low    O
molecular    O
mass    O
of    O
2000–3000    O
g    O
/    O
mol    O
on    O
average    O
.    O

This    O
coming    O
together    O
was    O
as    O
a    O
result    O
of    O
a    O
much    O
greater    O
understanding    O
of    O
the    O
cellular    O
and    O
molecular    O
biology    O
of    O
glycan    B-Polysaccharide114994004
.    O

Drugs    O
already    O
on    O
the    O
market    O
,    O
such    O
as    O
heparin    O
,    O
erythropoietin    O
and    O
a    O
few    O
anti    O
-    O
flu    O
drugs    O
have    O
proven    O
effective    O
and    O
highlight    O
the    O
importance    O
of    O
glycans    B-Polysaccharide114994004
as    O
a    O
new    O
class    O
of    O
drug    O
.    O

Although    O
these    O
glycans    B-Polysaccharide114994004
are    O
molecules    O
that    O
are    O
difficult    O
to    O
synthesize    O
in    O
a    O
reproducible    O
way    O
,    O
owing    O
to    O
their    O
complex    O
structure    O
,    O
this    O
new    O
field    O
of    O
research    O
is    O
highly    O
encouraging    O
for    O
the    O
future    O
.    O

This    O
enzyme    O
participates    O
in    O
amino    B-Polysaccharide114994004
sugar    I-Polysaccharide114994004
metabolism    O
and    O
glycan    B-Polysaccharide114994004
biosynthesis    O
.    O

,    O
Gilbert    O
has    O
been    O
dissecting    O
the    O
mechanisms    O
of    O
glycan    B-Polysaccharide114994004
utilisation    O
by    O
gut    O
bacteria    O
,    O
in    O
the    O
human    O
microbiota    O
.    O

This    O
enzyme    O
participates    O
in    O
the    O
biosynthesis    O
of    O
n    O
-    O
glycan    B-Polysaccharide114994004
and    O
glycan    O
structures    O
.    O

This    O
enzyme    O
participates    O
in    O
the    O
biosynthesis    O
of    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
and    O
glycan    B-Polysaccharide114994004
structures    O
.    O

This    O
enzyme    O
participates    O
in    O
the    O
biosynthesis    O
of    O
n    O
-    O
glycan    B-Polysaccharide114994004
and    O
glycan    O
structures    O
.    O

This    O
enzyme    O
participates    O
in    O
3    O
metabolic    O
pathways    O
:    O
the    O
lactoseries    O
and    O
neolactoseries    O
of    O
glycosphingolipid    O
biosynthesis    O
,    O
as    O
well    O
as    O
the    O
biosynthesis    O
of    O
glycan    B-Polysaccharide114994004
structures    O
.    O

The    O
basic    O
peptidoglycan    O
structure    O
of    O
both    O
Gram    O
-    O
positive    O
and    O
Gram    O
-    O
negative    O
bacteria    O
comprises    O
a    O
sheet    O
of    O
glycan    B-Polysaccharide114994004
chains    O
connected    O
by    O
short    O
cross    O
-    O
linking    O
polypeptides    O
.    O

This    O
enzyme    O
participates    O
in    O
glycosaminoglycan    B-Polysaccharide114994004
degradation    O
and    O
degradation    O
of    O
glycan    B-Polysaccharide114994004
structures    O
.    O

This    O
enzyme    O
participates    O
in    O
the    O
degradtaion    O
of    O
glycan    B-Polysaccharide114994004
structures    O
.    O

This    O
enzyme    O
is    O
also    O
called    O
almond    O
emulsin    O
fucosidase    O
I.    O
This    O
enzyme    O
participates    O
in    O
the    O
degradation    O
of    O
glycan    B-Polysaccharide114994004
structures    O
.    O

They    O
are    O
used    O
to    O
modify    O
the    O
glycan    B-Polysaccharide114994004
after    O
it    O
has    O
been    O
added    O
onto    O
the    O
lipid    O
to    O
represent    O
the    O
final    O
oligosaccharide    O
structure    O
.    O

Nitrostarch    B-Polysaccharide114994004

The    O
specific    O
reaction    O
involved    O
is    O
the    O
hydrolysis    O
of    O
the    O
1,4-beta    O
-    O
D    O
-    O
glycosidic    O
linkages    O
in    O
cellulose    O
,    O
hemicellulose    B-Polysaccharide114994004
,    O
lichenin    B-Polysaccharide114994004
,    O
and    O
cereal    O
beta    O
-    O
D    O
-    O
glucans    O
.    O

Two    O
problems    O
often    O
encountered    O
with    O
eating    O
lichens    O
is    O
that    O
they    O
usually    O
contain    O
mildly    O
toxic    O
secondary    O
compounds    O
,    O
and    O
that    O
lichen    B-Polysaccharide114994004
polysaccharides    I-Polysaccharide114994004
are    O
generally    O
indigestible    O
to    O
humans    O
.    O

The    O
microvilli    O
are    O
covered    O
with    O
glycocalyx    B-Polysaccharide114994004
,    O
consisting    O
of    O
peripheral    O
glycoproteins    O
that    O
can    O
attach    O
themselves    O
to    O
a    O
plasma    O
membrane    O
via    O
transmembrane    O
proteins    O
.    O

"    O
Vannellidae    O
"    O
are    O
surrounded    O
by    O
an    O
outer    O
covering    O
called    O
the    O
glycocalyx    B-Polysaccharide114994004
,    O
which    O
is    O
generally    O
10    O
-    O
20    O
nm    O
across    O
,    O
though    O
the    O
thickness    O
varies    O
among    O
species    O
.    O

In    O
certain    O
organisms    O
,    O
cells    O
are    O
covered    O
with    O
the    O
glycocalyx    B-Polysaccharide114994004
layer    O
,    O
which    O
can    O
be    O
modeled    O
as    O
a    O
polyelectrolyte    O
layer    O
with    O
a    O
volume    O
spread    O
electric    O
charge    O
.    O

Glycocalyx    B-Polysaccharide114994004

Glycocalyx    B-Polysaccharide114994004

Glycocalyx    B-Polysaccharide114994004

This    O
liquid    O
supplement    O
is    O
a    O
daily    O
,    O
oral    O
version    O
of    O
hyaluronic    O
acid    O
(    O
HA    O
)    O
,    O
also    O
called    O
sodium    B-Polysaccharide114994004
hyaluronate    I-Polysaccharide114994004
,    O
which    O
had    O
normally    O
been    O
administered    O
by    O
injection    O
.    O

OVDs    O
contain    O
one    O
or    O
more    O
of    O
the    O
following    O
substances    O
in    O
varying    O
concentrations    O
:    O
sodium    B-Polysaccharide114994004
hyaluronate    I-Polysaccharide114994004
,    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
or    O
hydroxypropyl    B-Polysaccharide114994004
methylcellulose    I-Polysaccharide114994004
.    O

The    O
plant    O
's    O
seeds    O
are    O
a    O
commercial    O
source    O
of    O
cassia    B-Polysaccharide114994004
gum    I-Polysaccharide114994004
,    O
a    O
food    O
additive    O
usually    O
used    O
as    O
a    O
thickener    O
and    O
named    O
for    O
the    O
Chinese    O
Senna    O
's    O
former    O
placement    O
in    O
the    O
genus    O
"    O
Cassia    O
"    O
.    O
Roasted    O
and    O
ground    O
,    O
the    O
seeds    O
have    O
also    O
been    O
used    O
as    O
a    O
substitute    O
for    O
coffee    O
.    O

When    O
a    O
paraperigone    O
is    O
present    O
it    O
consists    O
of    O
basal    O
appendages    O
that    O
are    O
diminutive    O
,    O
membranous    O
,    O
bristle    O
-    O
like    O
,    O
and    O
forming    O
a    O
fimbriate    O
-    O
lacerate    O
or    O
callose    B-Polysaccharide114994004
ring    O
,    O
partly    O
adnate    O
to    O
the    O
throat    O
of    O
the    O
perigone    O
,    O
surrounding    O
the    O
fascicle    O
of    O
the    O
stamen    O
.    O

"    O
Galiella    O
"    O
includes    O
bulgarioid    O
species    O
(    O
those    O
with    O
a    O
morphology    O
similar    O
to    O
those    O
in    O
"    O
Bulgaria    O
"    O
)    O
with    O
spores    O
featuring    O
surface    O
warts    O
that    O
are    O
made    O
of    O
callose    B-Polysaccharide114994004
-    O
pectic    O
substances    O
that    O
stain    O
with    O
methyl    O
blue    O
dye    O
.    O

Cell    O
wall    O
reinforcement    O
(    O
callose    B-Polysaccharide114994004
,    O
lignin    O
,    O
suberin    O
,    O
cell    O
wall    O
proteins    O
)    O

Since    O
2005    O
,    O
Avebe    O
produces    O
a    O
GMO    O
-    O
free    O
amylopectin    B-Polysaccharide114994004
waxy    B-Polysaccharide114994004
potato    I-Polysaccharide114994004
starch    I-Polysaccharide114994004
(    O
Eliane    O
)    O
and    O
is    O
investing    O
in    O
a    O
new    O
refining    O
technique    O
to    O
produce    O
native    O
potato    O
protein    O
(    O
Solanic    O
)    O
for    O
food    O
applications    O
.    O

Waxy    B-Polysaccharide114994004
potato    I-Polysaccharide114994004
starch    I-Polysaccharide114994004
is    O
used    O
in    O
industrial    O
procedures    O
to    O
make    O
yarn    O
stronger    O
and    O
paper    O
glossier    O
;    O
it    O
also    O
makes    O
spray    O
concrete    O
adhere    O
better    O
to    O
walls    O
.    O

Reviparin    B-Polysaccharide114994004
is    O
an    O
antithrombotic    O
and    O
belongs    O
to    O
the    O
group    O
of    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
.    O

fondaparinux    B-Polysaccharide114994004
sodium    I-Polysaccharide114994004
(    O
USAN    O
)    O

For    O
example    O
,    O
the    O
drug    O
Fondaparinux    B-Polysaccharide114994004
is    O
an    O
indirect    O
inhibitor    O
of    O
Factor    O
Xa    O
.    O

Treatment    O
with    O
fondaparinux    B-Polysaccharide114994004
reduces    O
the    O
risk    O
of    O
subsequent    O
venous    O
thromboembolism    O
.    O

Valtrex    O
is    O
offered    O
in    O
250    O
mg    O
,    O
500    O
mg    O
,    O
and    O
1    O
gram    O
tablets    O
,    O
the    O
active    O
ingredient    O
being    O
valacyclovir    O
hydrochloride    O
,    O
with    O
the    O
inactive    O
ingredients    O
carnauba    O
wax    O
,    O
colloidal    O
silicon    O
dioxide    O
,    O
crospovidone    O
,    O
FD&C    O
Blue    O
No    O
.    O
2    O
Lake    O
,    O
hypromellose    B-Polysaccharide114994004
,    O
magnesium    O
stearate    O
,    O
microcrystalline    B-Polysaccharide114994004
cellulose    I-Polysaccharide114994004
,    O
polyethylene    O
glycol    O
,    O
polysorbate    O
80    O
,    O
povidone    O
,    O
and    O
titanium    O
dioxide    O
.    O

A    O
complete    O
list    O
of    O
the    O
ingredients    O
includes    O
:    O
soybean    O
oil    O
,    O
water    O
,    O
egg    O
yolk    O
,    O
gluconic    O
acid    O
,    O
yeast    O
extract    O
,    O
stabilizer    O
(    O
microcrystalline    B-Polysaccharide114994004
cellulose    I-Polysaccharide114994004
,    O
modified    O
food    O
starch    O
,    O
xanthan    O
gum    O
,    O
guar    O
gum    O
,    O
gum    O
arabic    O
)    O
,    O
cultured    O
dextrose    O
,    O
salt    O
,    O
sugar    O
,    O
dehydrated    O
garlic    O
,    O
paprika    O
,    O
dehydrated    O
onion    O
,    O
spice    O
,    O
natural    O
smoke    O
flavor    O
,    O
natural    O
flavors    O
,    O
tocopherols    O
,    O
calcium    O
disodium    O
EDTA    O
,    O
and    O
autolyzed    O
yeast    O
extract    O
.    O

Other    O
soluble    O
fiber    O
forms    O
such    O
as    O
glucomannan    B-Polysaccharide114994004
have    O
also    O
been    O
studied    O
in    O
relationship    O
to    O
blood    O
sugar    O
and    O
fat    O
digestion    O
in    O
obese    O
patients    O
.    O

Commercial    O
jellies    O
used    O
in    O
East    O
Asian    O
cuisines    O
include    O
the    O
glucomannan    B-Polysaccharide114994004
polysaccharide    O
gum    O
used    O
to    O
make    O
"    O
lychee    O
cups    O
"    O
from    O
the    O
konjac    O
plants    O
,    O
and    O
aiyu    O
or    O
ice    O
jelly    O
from    O
the    O
"    O
Ficus    O
pumila    O
"    O
climbing    O
fig    O
plant    O
.    O

Sizofiran    B-Polysaccharide114994004
is    O
a    O
beta    O
-    O
glucan    O
,    O
also    O
known    O
as    O
schizophyllan    B-Polysaccharide114994004
and    O
abbreviated    O
as    O
SPG    O
in    O
many    O
papers    O
.    O

For    O
example    O
,    O
many    O
Japanese    O
individuals    O
possess    O
the    O
genes    O
for    O
the    O
consumption    O
of    O
the    O
algal    O
polysaccharide    O
porphyran    B-Polysaccharide114994004
in    O
their    O
microbiomes    O
,    O
which    O
are    O
rarely    O
found    O
in    O
North    O
American    O
and    O
European    O
individuals    O
.    O

Pleuran    B-Polysaccharide114994004
is    O
an    O
insoluble    O
polysaccharide    O
(    O
β-(1,3/1,6)-D    O
-    O
glucan    O
)    O
,    O
isolated    O
from    O
"    O
Pleurotus    O
ostreatus    O
"    O
.    O

In    O
ancient    O
times    O
,    O
the    O
Kingdom    O
of    O
Punt    O
,    O
which    O
is    O
believed    O
by    O
several    O
Egyptologists    O
to    O
have    O
been    O
situated    O
in    O
the    O
area    O
of    O
modern    O
-    O
day    O
Somalia    O
,    O
had    O
a    O
steady    O
trade    O
link    O
with    O
the    O
Ancient    O
Egyptians    O
and    O
exported    O
precious    O
natural    O
resources    O
such    O
as    O
myrrh    O
,    O
frankincense    O
and    O
gum    B-Polysaccharide114994004
.    O

In    O
ancient    O
times    O
,    O
the    O
port    O
city    O
of    O
Botiala    O
transported    O
goods    O
such    O
as    O
aromatic    O
woods    O
,    O
gum    B-Polysaccharide114994004
and    O
incense    O
to    O
Indian    O
,    O
Persian    O
and    O
Arab    O
merchants    O

Mundus    O
–    O
Ancient    O
port    O
engaged    O
in    O
the    O
fragrant    O
gum    B-Polysaccharide114994004
and    O
cinnamon    O
trade    O
with    O
the    O
Hellenic    O
world    O
.    O

An    O
organic    O
compound    O
such    O
as    O
gum    B-Polysaccharide114994004
or    O
glue    O
may    O
be    O
added    O
for    O
binding    O
.    O

The    O
drug    O
,    O
along    O
with    O
gum    B-Polysaccharide114994004
,    O
fatty    O
oils    O
,    O
and    O
malates    O
of    O
magnesium    O
and    O
calcium    O
,    O
contains    O
also    O
about    O
1%    O
of    O
cubebic    O
acid    O
,    O
and    O
about    O
6%    O
of    O
a    O
resin    O
.    O

The    O
paintings    O
are    O
not    O
frescoes    O
but    O
instead    O
executed    O
on    O
an    O
earthen    O
render    O
with    O
mineral    O
and    O
organic    O
pigments    O
and    O
gum    B-Polysaccharide114994004
or    O
glue    O
binders    O
.    O

Mucic    O
acid    O
,    O
C6H10O8    O
or    O
HOOC-(CHOH)4-COOH    O
,    O
(    O
also    O
known    O
as    O
galactaric    O
or    O
meso    O
-    O
galactaric    O
acid    O
)    O
is    O
an    O
aldaric    O
acid    O
obtained    O
by    O
nitric    O
acid    O
oxidation    O
of    O
galactose    O
or    O
galactose    O
-    O
containing    O
compounds    O
such    O
as    O
lactose    O
,    O
dulcite    O
,    O
quercite    O
,    O
and    O
most    O
varieties    O
of    O
gum    B-Polysaccharide114994004
.    O

At    O
the    O
1215    O
siege    O
of    O
Rochester    O
Castle    O
,    O
King    O
John    O
ordered    O
that    O
fat    O
from    O
40    O
pigs    O
be    O
used    O
to    O
set    O
fire    O
to    O
the    O
mines    O
beneath    O
the    O
keep    O
,    O
which    O
caused    O
it    O
to    O
collapse    O
,    O
a    O
cheap    O
and    O
effective    O
technique    O
in    O
place    O
of    O
the    O
more    O
complicated    O
mixture    O
of    O
sulfur    O
,    O
tallow    O
,    O
gum    B-Polysaccharide114994004
,    O
pitch    O
and    O
quicksilver    O
he    O
had    O
used    O
in    O
France    O
the    O
previous    O
year    O
.    O

Its    O
cecum    O
is    O
larger    O
than    O
usual    O
to    O
allow    O
for    O
the    O
greater    O
period    O
of    O
time    O
gum    B-Polysaccharide114994004
takes    O
to    O
break    O
down    O
in    O
the    O
stomach    O
.    O

Food    O
thickeners    O
frequently    O
are    O
based    O
on    O
either    O
polysaccharides    O
(    O
starches    O
,    O
vegetable    B-Polysaccharide114994004
gum    I-Polysaccharide114994004
,    O
and    O
pectin    O
)    O
,    O
or    O
proteins    O
.    O

Vegetable    B-Polysaccharide114994004
gum    I-Polysaccharide114994004
used    O
as    O
food    O
thickeners    O
include    O
alginin    O
,    O
guar    O
gum    O
,    O
locust    O
bean    O
gum    O
,    O
and    O
xanthan    O
gum    O
.    O

Typical    O
gelling    O
agents    O
include    O
natural    B-Polysaccharide114994004
gum    I-Polysaccharide114994004
,    O
starches    O
,    O
pectins    O
,    O
agar    O
-    O
agar    O
and    O
gelatin    O
.    O

Locust    O
bean    O
gum    O
(    O
E410    O
,    O
a    O
natural    B-Polysaccharide114994004
gum    I-Polysaccharide114994004
polysaccharide    O
from    O
the    O
seeds    O
of    O
the    O
Carob    O
tree    O
)    O

Thickening    O
agents    O
used    O
in    O
cosmetics    O
or    O
personal    O
hygiene    O
products    O
include    O
viscous    O
liquids    O
such    O
as    O
polyethylene    O
glycol    O
,    O
synthetic    O
polymers    O
such    O
as    O
carbomer    O
(    O
a    O
trade    O
name    O
for    O
polyacrylic    O
acid    O
)    O
and    O
vegetable    B-Polysaccharide114994004
gum    I-Polysaccharide114994004
.    O

The    O
new    O
drug    O
,    O
Alfaxan    O
,    O
used    O
a    O
cyclodextrin    B-Polysaccharide114994004
as    O
a    O
carrier    O
agent    O
to    O
make    O
alfaxalone    O
more    O
water    O
soluble    O
rather    O
than    O
Camphor    O
EL    O
.    O

Cyclodextrins    B-Polysaccharide114994004
are    O
cap    O
structures    O
with    O
a    O
hydrophilic    O
exterior    O
but    O
a    O
hydrophobic    O
interior    O
.    O

Crystal    O
structure    O
of    O
a    O
rotaxane    O
with    O
an    O
cyclodextrin    B-Polysaccharide114994004
macrocycle    O
..    O

He    O
also    O
showed    O
that    O
cyclodextrin    B-Polysaccharide114994004
can    O
be    O
used    O
to    O
investigate    O
catalysis    O
of    O
organic    O
reactions    O
within    O
the    O
scope    O
of    O
host    O
-    O
guest    O
chemistry    O
.    O

Chemical    O
-    O
based    O
transfection    O
can    O
be    O
divided    O
into    O
several    O
kinds    O
:    O
cyclodextrin    B-Polysaccharide114994004
,    O
polymers    O
,    O
liposomes    O
,    O
or    O
nanoparticles    O
(    O
with    O
or    O
without    O
chemical    O
or    O
viral    O
functionalization    O
.    O

More    O
recently    O
,    O
the    O
term    O
refers    O
to    O
many    O
molecular    O
hosts    O
,    O
including    O
calixarenes    O
and    O
cyclodextrin    B-Polysaccharide114994004
and    O
even    O
some    O
inorganic    O
polymers    O
such    O
as    O
zeolites    O
.    O

When    O
complexed    O
with    O
β-cyclodextrin    B-Polysaccharide114994004
,    O
it    O
has    O
on    O
average    O
a    O
1.5    O
hour    O
protection    O
duration    O
against    O
mosquitoes    O
.    O

An    O
oral    O
formulation    O
of    O
the    O
drug    O
with    O
cyclodextrin    B-Polysaccharide114994004
was    O
developed    O
and    O
Ivax    O
and    O
Serono    O
,    O
and    O
then    O
Merck    O
KGgA    O
conducted    O
several    O
clinical    O
studies    O
.    O

Cyclodextrin    B-Polysaccharide114994004
,    O
calixarenes    O
,    O
cucurbiturils    O
and    O
crown    O
ethers    O
are    O
readily    O
synthesized    O
in    O
large    O
quantities    O
,    O
and    O
are    O
therefore    O
convenient    O
for    O
use    O
in    O
supramolecular    O
systems    O
.    O

In    O
addition    O
,    O
the    O
cell    O
walls    O
of    O
all    O
"    O
Equisetum    O
"    O
species    O
tested    O
contain    O
mixed-linkage    B-Polysaccharide114994004
glucan    I-Polysaccharide114994004
(    O
MLG    O
)    O
,    O
a    O
polysaccharide    O
which    O
,    O
until    O
recently    O
,    O
was    O
thought    O
to    O
be    O
confined    O
to    O
the    O
Poales    O
.    O

Embolex    B-Polysaccharide114994004

Pentastarch    B-Polysaccharide114994004

Glucomannan    O
with    O
α-(1→6)-linked    O
galactose    O
units    O
in    O
side    O
branches    O
is    O
called    O
galactoglucomannan    B-Polysaccharide114994004
.    O

The    O
sequence    O
of    O
branching    O
information    O
in    O
a    O
arabinoxylan    B-Polysaccharide114994004
molecule    O
.    O

The    O
smoothness    O
of    O
oatmeal    O
stouts    O
comes    O
from    O
the    O
high    O
content    O
of    O
proteins    O
,    O
lipids    O
,    O
and    O
gums    B-Polysaccharide114994004
imparted    O
by    O
the    O
use    O
of    O
oats    O
.    O

It    O
is    O
important    O
to    O
ensure    O
that    O
reaction    O
parameters    O
such    O
as    O
temperature    O
and    O
salt    O
concentration    O
are    O
suitable    O
to    O
maintain    O
the    O
DNA    O
in    O
a    O
single    O
-    O
stranded    O
conformation    O
and    O
allow    O
for    O
complete    O
conversion    O
.    O
Embedding    O
the    O
DNA    O
in    O
agarose    B-Polysaccharide114994004
gel    O

In    O
this    O
case    O
,    O
agarose    B-Polysaccharide114994004
is    O
injected    O
and    O
this    O
triggers    O
local    O
hypoxia    B-Polysaccharide114994004
,    O
which    O
then    O
results    O
in    O
the    O
differentiation    O
of    O
the    O
periosteal    O
MSCs    O
into    O
articular    O
chondrocytes    O
,    O
i.e.    O
cells    O
similar    O
to    O
those    O
found    O
in    O
the    O
joint    O
cartilage    O
.    O

Agarose    O
gel    O
electrophoresis    O
is    O
a    O
method    O
of    O
gel    O
electrophoresis    O
used    O
in    O
biochemistry    O
,    O
molecular    O
biology    O
,    O
genetics    O
,    O
and    O
clinical    O
chemistry    O
to    O
separate    O
a    O
mixed    O
population    O
of    O
macromolecules    O
such    O
as    O
DNA    O
or    O
proteins    O
in    O
a    O
matrix    O
of    O
agarose    B-Polysaccharide114994004
,    O
one    O
of    O
the    O
two    O
main    O
components    O
of    O
agar    O
.    O

Agarose    B-Polysaccharide114994004
gel    O
is    O
a    O
three    O
-    O
dimensional    O
matrix    O
formed    O
of    O
helical    O
agarose    O
molecules    O
in    O
supercoiled    O
bundles    O
that    O
are    O
aggregated    O
into    O
three    O
-    O
dimensional    O
structures    O
with    O
channels    O
and    O
pores    O
through    O
which    O
biomolecules    O
can    O
pass    O
.    O

The    O
resulting    O
samples    O
are    O
subsequently    O
run    O
on    O
an    O
electrophoresis    O
gel    O
,    O
typically    O
on    O
agarose    B-Polysaccharide114994004
gel    O
.    O

These    O
can    O
be    O
run    O
in    O
either    O
agarose    B-Polysaccharide114994004
or    O
polyacrylamide    O
gels    O
.    O

Congenital    O
tracheal    O
collapse    O
appears    O
to    O
be    O
caused    O
by    O
a    O
deficiency    O
of    O
normal    O
components    O
of    O
tracheal    O
ring    O
cartilage    O
like    O
glycosaminoglycan    B-Polysaccharide114994004
,    O
glycoproteins    O
,    O
calcium    O
,    O
and    O
chondroitin    B-Polysaccharide114994004
.    O

In    O
enzymology    O
,    O
a    O
glucuronate-2-sulfatase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
chemical    O
reaction    O
of    O
cleaving    O
off    O
the    O
2-sulfate    O
groups    O
of    O
the    O
2-O    O
-    O
sulfo    O
-    O
D    O
-    O
glucuronate    O
residues    O
of    O
chondroitin    B-Polysaccharide114994004
sulfate    O
,    O
heparin    O
and    O
heparitin    O
sulfate    O
.    O

In    O
enzymology    O
,    O
a    O
N    O
-    O
acetylgalactosamine-6-sulfatase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
chemical    O
reaction    O
of    O
cleaving    O
off    O
the    O
6-sulfate    O
groups    O
of    O
the    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
galactosamine    O
6-sulfate    O
units    O
of    O
the    O
macromolecule    O
chondroitin    B-Polysaccharide114994004
sulfate    O
and    O
,    O
similarly    O
,    O
of    O
the    O
D    O
-    O
galactose    O
6-sulfate    O
units    O
of    O
the    O
macromolecule    O
keratan    O
sulfate    O
.    O

This    O
enzyme    O
participates    O
in    O
aminosugars    B-Polysaccharide114994004
metabolism    I-Polysaccharide114994004
.    O

This    O
enzyme    O
participates    O
in    O
aminosugars    B-Polysaccharide114994004
metabolism    I-Polysaccharide114994004
.    O

This    O
enzyme    O
participates    O
in    O
7    O
metabolic    O
pathways    O
:    O
glycolysis    O
/    O
gluconeogenesis    O
,    O
fructose    O
and    O
mannose    O
metabolism    O
,    O
galactose    O
metabolism    O
,    O
ascorbate    O
and    O
aldarate    O
metabolism    O
,    O
starch    O
and    O
sucrose    O
metabolism    O
,    O
aminosugars    B-Polysaccharide114994004
metabolism    I-Polysaccharide114994004
,    O
and    O
phosphotransferase    O
system    O
(    O
pts    O
)    O
.    O

This    O
enzyme    O
participates    O
in    O
aminosugars    B-Polysaccharide114994004
metabolism    I-Polysaccharide114994004
.    O

D    O
-    O
Glucosamine    O
is    O
made    O
naturally    O
in    O
the    O
form    O
of    O
glucosamine-6-phosphate    O
,    O
and    O
is    O
the    O
biochemical    O
precursor    O
of    O
all    O
nitrogen-containing    B-Polysaccharide114994004
sugars    I-Polysaccharide114994004
.    O

This    O
enzyme    O
participates    O
in    O
aminosugars    B-Polysaccharide114994004
metabolism    I-Polysaccharide114994004
.    O

Nadroparin    B-Polysaccharide114994004
(    O
trade    O
name    O
,    O
Fraxiparine    O
or    O
Fraxodi    O
)    O
is    O
an    O
anticoagulant    O
belonging    O
to    O
a    O
class    O
of    O
drugs    O
called    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
(    O
LMWHs    O
)    O
.    O

Glucuronoxylans    B-Polysaccharide114994004
are    O
the    O
primary    O
components    O
of    O
hemicellulose    B-Polysaccharide114994004
as    O
found    O
in    O
hardwood    O
trees    O
,    O
for    O
example    O
birch    O
.    O

Sizofiran    B-Polysaccharide114994004
is    O
a    O
beta    O
-    O
glucan    O
,    O
also    O
known    O
as    O
schizophyllan    B-Polysaccharide114994004
and    O
abbreviated    O
as    O
SPG    O
in    O
many    O
papers    O
.    O

Normal    O
coconut    O
flesh    O
mostly    O
consists    O
of    O
galactomannan    B-Polysaccharide114994004
as    O
a    O
source    O
of    O
energy    O
.    O

These    O
galactomannan    B-Polysaccharide114994004
are    O
associated    O
with    O
allowing    O
an    O
organism    O
to    O
endure    O
harsh    O
environments    O
(    O
through    O
stabilization    O
of    O
the    O
membrane    O
)    O
,    O
such    O
as    O
high    O
temperatures    O
.    O

The    O
GFR    O
can    O
be    O
determined    O
by    O
injecting    O
inulin    O
or    O
the    O
inulin    O
-    O
analog    O
sinistrin    B-Polysaccharide114994004
into    O
the    O
plasma    O
.    O

There    O
are    O
three    O
main    O
steps    O
that    O
combine    O
Cohn    O
fractionation    O
with    O
chromatography    O
:    O
1    O
)    O
factors    O
I    O
,    O
II    O
,    O
and    O
III    O
are    O
removed    O
via    O
cold    O
ethanol    O
fractionation    O
,    O
2    O
)    O
Sepharose    B-Polysaccharide114994004
fast    O
flow    O
ion    O
exchange    O
and    O
sepharose    O
fast    O
flow    O
chromatography    O
procedures    O
are    O
run    O
,    O
and    O
3    O
)    O
gel    O
filtration    O
is    O
run    O
.    O

Materials    O
which    O
have    O
been    O
used    O
include    O
poly    O
(    O
glycolic    O
acid    O
)    O
,    O
poly(lactic    O
-    O
co    O
-    O
glycolic    O
acid    O
)    O
,    O
iron    O
-    O
oxide    O
,    O
liposomes    O
,    O
lipid    O
bilayers    O
,    O
sepharose    B-Polysaccharide114994004
,    O
polystyrene    O
and    O
Polyisocyanopeptides    O

Active    B-Polysaccharide114994004
hexose    I-Polysaccharide114994004
correlated    I-Polysaccharide114994004
compound    I-Polysaccharide114994004

The    O
loading    O
buffer    O
contains    O
a    O
dense    O
compound    O
,    O
which    O
may    O
be    O
glycerol    O
,    O
sucrose    O
,    O
or    O
Ficoll    B-Polysaccharide114994004
,    O
that    O
raises    O
the    O
density    O
of    O
the    O
sample    O
so    O
that    O
the    O
DNA    O
sample    O
may    O
sink    O
to    O
the    O
bottom    O
of    O
the    O
well    O
.    O

Other    O
molecules    O
that    O
have    O
the    O
potential    O
to    O
promote    O
nerve    O
repair    O
are    O
:    O
hyaluronic    B-Polysaccharide114994004
acid    I-Polysaccharide114994004
,    O
fibrinogen    O
,    O
fibrin    O
gels    O
,    O
self    O
-    O
assembling    O
peptide    O
scaffolds    O
,    O
alginate    O
,    O
agarose    B-Polysaccharide114994004
,    O
and    O
chitosan    B-Polysaccharide114994004
.    O

The    O
paint    O
detackifiers    O
commonly    O
added    O
to    O
these    O
systems    O
are    O
either    O
melamine    O
-    O
formaldehyde    O
based    O
,    O
based    O
upon    O
acrylic    O
acid    O
chemistry    O
,    O
or    O
chitosan    B-Polysaccharide114994004
.    O

Proteic    O
materials    O
,    O
such    O
as    O
collagen    O
or    O
fibrin    O
,    O
and    O
polysaccharidic    O
materials    O
,    O
like    O
chitosan    B-Polysaccharide114994004
or    O
glycosaminoglycan    B-Polysaccharide114994004
(    O
GAGs    O
)    O
,    O
have    O
all    O
proved    O
suitable    O
in    O
terms    O
of    O
cell    O
compatibility    O
,    O
but    O
some    O
issues    O
with    O
potential    O
immunogenicity    O
still    O
remains    O
.    O

This    O
backbone    O
consists    O
of    O
well    O
-    O
established    O
and    O
safe    O
polymers    O
such    O
as    O
chitosan    B-Polysaccharide114994004
or    O
poly(acrylic    O
acid    O
)    O
.    O

Examples    O
of    O
natural    O
polymers    O
include    O
collagen    O
,    O
cellulose    O
,    O
silk    O
fibroin    O
,    O
keratin    O
,    O
gelatin    O
and    O
polysaccharides    O
such    O
as    O
chitosan    B-Polysaccharide114994004
and    O
alginate    O
.    O

Major    O
examples    O
of    O
natural    O
polymers    O
used    O
in    O
scaffold    O
production    O
are    O
collagen    O
,    O
cellulose    O
,    O
silk    O
fibroin    O
,    O
keratin    O
,    O
gelatin    O
and    O
polysaccharides    O
such    O
as    O
chitosan    B-Polysaccharide114994004
and    O
alginate    O
.    O

Similarly    O
,    O
keratin    O
,    O
gelatin    O
,    O
chitosan    B-Polysaccharide114994004
and    O
alginate    O
demonstrate    O
excellent    O
biocompatibility    O
and    O
bioactivity    O
in    O
scaffolds    O
.    O

pKa    O
values    O
of    O
chitosan    B-Polysaccharide114994004
can    O
be    O
calculated    O
from    O
the    O
dependency    O
of    O
electrophoretic    O
mobility    O
values    O
on    O
pH    O
and    O
charge    O
density    O
.    O

dalteparin    B-Polysaccharide114994004
sodium    I-Polysaccharide114994004
(    O
INN    O
)    O

Fragmin    B-Polysaccharide114994004

dextran    B-Polysaccharide114994004
(    O
INN    O
)    O

LDL    O
apheresis    O
works    O
by    O
leading    O
venous    O
blood    O
through    O
a    O
column    O
containing    O
beads    O
coated    O
with    O
antibodies    O
to    O
apolipoprotein    O
B    O
(    O
the    O
main    O
protein    O
of    O
LDL    O
particles    O
)    O
,    O
dextran    B-Polysaccharide114994004
sulfate    O
cellulose    O
beads    O
,    O
modified    O
polyacrylate    O
beads    O
,    O
or    O
by    O
precipitating    O
LDL    O
with    O
heparin    O
at    O
low    O
pH    O
,    O
double    O
membrane    O
filtration    O
or    O
immunoadsorption    O
utilizing    O
Lp(a)-specific    O
antibodies    O
.    O

Many    O
other    O
therapies    O
have    O
been    O
used    O
with    O
varying    O
degrees    O
of    O
success    O
,    O
including    O
hyperbaric    O
oxygen    O
,    O
dapsone    O
,    O
antihistamines    O
(    O
e.g.    O
,    O
cyproheptadine    O
)    O
,    O
antibiotics    O
,    O
dextran    B-Polysaccharide114994004
,    O
glucocorticoids    O
,    O
vasodilators    O
,    O
heparin    O
,    O
nitroglycerin    O
,    O
electric    O
shock    O
,    O
curettage    O
,    O
surgical    O
excision    O
,    O
and    O
antivenom    O
.    O

They    O
also    O
demonstrated    O
the    O
advantage    O
of    O
having    O
a    O
polymeric    O
spacer    O
between    O
the    O
antibody    O
and    O
the    O
drug    O
and    O
showed    O
the    O
effectiveness    O
of    O
conjugating    O
simple    O
polymers    O
such    O
as    O
dextran    B-Polysaccharide114994004
for    O
drug    O
delivery    O
and    O
targeting    O
.    O

Polymers    O
,    O
such    O
as    O
dextrans    B-Polysaccharide114994004
and    O
polyethylene    O
glycols    O
,    O
are    O
frequently    O
used    O
to    O
precipitate    O
proteins    O
because    O
they    O
have    O
low    O
flammability    O
and    O
are    O
less    O
likely    O
to    O
denature    O
biomaterials    O
than    O
isoelectric    O
precipitation    O
.    O

"    O
Lactobacillus    O
brevis    O
"    O
has    O
been    O
identified    O
as    O
the    O
species    O
responsible    O
for    O
the    O
production    O
of    O
the    O
polysaccharide    O
(    O
dextran    B-Polysaccharide114994004
)    O
that    O
forms    O
the    O
grains    O
.    O

Telluria    O
mixta    O
(    O
formerly    O
called    O
"    O
Pseudomonas    O
mixta    O
"    O
)    O
is    O
a    O
species    O
of    O
Gram    O
-    O
negative    O
soil    O
bacteria    O
that    O
actively    O
degrades    O
polysaccharides    O
including    O
dextran    B-Polysaccharide114994004
,    O
inulin    O
,    O
pectate    O
,    O
starch    O
,    O
and    O
xylan    B-Polysaccharide114994004
.    O

Viridans    O
streptococci    O
have    O
the    O
unique    O
ability    O
to    O
synthesize    O
dextran    B-Polysaccharide114994004
from    O
glucose    O
,    O
which    O
allows    O
them    O
to    O
adhere    O
to    O
fibrin    O
-    O
platelet    O
aggregates    O
at    O
damaged    O
heart    O
valves    O
.    O

|    O
Zymosan    B-Polysaccharide114994004
(    O
a    O
beta    O
-    O
glucan    O
)    O

Glucomannan    O
is    O
also    O
a    O
hemicellulose    B-Polysaccharide114994004
that    O
is    O
present    O
in    O
large    O
amounts    O
in    O
the    O
wood    O
of    O
conifers    O
and    O
in    O
smaller    O
amounts    O
in    O
the    O
wood    O
of    O
dicotyledons    O
.    O

“    O
This    O
work    O
shows    O
that    O
we    O
can    O
reduce    O
one    O
of    O
the    O
most    O
expensive    O
parts    O
of    O
the    O
biofuel    O
production    O
process    O
,    O
the    O
addition    O
of    O
enzymes    O
to    O
depolymerize    O
cellulose    O
and    O
hemicellulose    B-Polysaccharide114994004
into    O
fermentable    O
sugars    O
,    O
”    O
says    O
Jay    O
Keasling    O
,    O
CEO    O
of    O
JBEI    O
and    O
leader    O
of    O
this    O
research    O
.    O

Glucuronoxylans    B-Polysaccharide114994004
are    O
the    O
primary    O
components    O
of    O
hemicellulose    B-Polysaccharide114994004
as    O
found    O
in    O
hardwood    O
trees    O
,    O
for    O
example    O
birch    O
.    O

Polysaccharides    O
are    O
present    O
in    O
plant    O
cellular    O
cell    O
walls    O
in    O
a    O
compact    O
fiber    O
form    O
where    O
they    O
are    O
mainly    O
composed    O
of    O
cellulose    O
and    O
hemicellulose    B-Polysaccharide114994004
.    O

Generally    O
,    O
in    O
cabinets    O
or    O
display    O
cases    O
that    O
are    O
entirely    O
or    O
partially    O
made    O
of    O
wood    O
,    O
the    O
hydrolysis    O
of    O
acetyl    O
groups    O
in    O
the    O
wood    O
hemicellulose    B-Polysaccharide114994004
creates    O
acetic    O
acid    O
.    O

The    O
biomass    O
is    O
primarily    O
composed    O
of    O
carbohydrate    O
polymers    O
cellulose    O
,    O
hemicellulose    B-Polysaccharide114994004
,    O
and    O
an    O
aromatic    O
polymer    O
(    O
lignin    O
)    O
.    O

It    O
accomplishes    O
this    O
by    O
producing    O
enzymes    O
capable    O
of    O
breaking    O
down    O
the    O
three    O
major    O
biochemical    O
components    O
of    O
plant    O
cell    O
walls    O
found    O
in    O
litter    O
:    O
cellulose    O
,    O
hemicellulose    B-Polysaccharide114994004
and    O
lignin    O
.    O

The    O
specific    O
reaction    O
involved    O
is    O
the    O
hydrolysis    O
of    O
the    O
1,4-beta    O
-    O
D    O
-    O
glycosidic    O
linkages    O
in    O
cellulose    O
,    O
hemicellulose    B-Polysaccharide114994004
,    O
lichenin    B-Polysaccharide114994004
,    O
and    O
cereal    O
beta    O
-    O
D    O
-    O
glucans    O
.    O

Additionally    O
,    O
"    O
A.    O
versicolor    O
"    O
has    O
high    O
activity    O
levels    O
of    O
xylanase    O
,    O
an    O
enzyme    O
that    O
breaks    O
down    O
hemicellulose    B-Polysaccharide114994004
in    O
plant    O
cell    O
walls    O
.    O

No    O
hemicellulose    B-Polysaccharide114994004
or    O
lignin    O
to    O
be    O
removed    O

In    O
industrial    O
chemistry    O
,    O
black    O
liquor    O
is    O
the    O
waste    O
product    O
from    O
the    O
kraft    O
process    O
when    O
digesting    O
pulpwood    O
into    O
paper    O
pulp    O
removing    O
lignin    O
,    O
hemicellulose    B-Polysaccharide114994004
and    O
other    O
extractives    O
from    O
the    O
wood    O
to    O
free    O
the    O
cellulose    O
fibers    O
.    O

Cellulose    O
and    O
hemicellulose    B-Polysaccharide114994004
is    O
degraded    O
to    O
aliphatic    O
carboxylic    O
acid    O
soaps    O
and    O
hemicellulose    O
fragments    O
.    O

It    O
has    O
been    O
used    O
in    O
applications    O
such    O
as    O
characterizing    O
enzymes    O
involved    O
in    O
hemicellulose    B-Polysaccharide114994004
degradation    O
,    O
determining    O
the    O
structure    O
of    O
hemicellulose    O
polysaccharides    O
,    O
and    O
analysis    O
of    O
enzymatic    O
cleavage    O
of    O
cellulose    O
products    O
.    O

Grown    O
in    O
axenic    O
culture    O
in    O
the    O
laboratory    O
,    O
the    O
fungus    O
mycelium    O
has    O
been    O
shown    O
to    O
degrade    O
(    O
in    O
addition    O
to    O
lignin    O
and    O
cellulose    O
)    O
hemicellulose    B-Polysaccharide114994004
,    O
protein    O
,    O
soluble    O
carbohydrates    O
,    O
and    O
purified    O
xylan    B-Polysaccharide114994004
and    O
pectin    O
using    O
enzymes    O
such    O
as    O
polyphenol    O
oxidases    O
,    O
cellulases    O
,    O
and    O
catalase    O
.    O

It    O
causes    O
a    O
brown    O
rot    O
in    O
wood    O
,    O
whereby    O
it    O
breaks    O
down    O
the    O
hemicellulose    B-Polysaccharide114994004
and    O
cellulose    O
to    O
cause    O
a    O
brown    O
discoloration    O
,    O
and    O
the    O
subsequent    O
cracking    O
of    O
the    O
wood    O
into    O
roughly    O
cubical    O
pieces    O
.    O

These    O
proteoglycans    O
share    O
a    O
homologous    O
globular    O
N    O
-    O
terminal    O
,    O
C    O
-    O
terminal    O
,    O
and    O
glycosaminoglycan    B-Polysaccharide114994004
(    O
GAG    O
)    O
binding    O
regions    O
.    O

Other    O
medications    O
have    O
been    O
shown    O
to    O
be    O
useful    O
in    O
topical    O
treatment    O
of    O
refractory    O
ulcers    O
,    O
including    O
glycosaminoglycan    B-Polysaccharide114994004
such    O
as    O
sodium    B-Polysaccharide114994004
hyaluronate    I-Polysaccharide114994004
and    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
aminocaproic    O
acid    O
,    O
and    O
acetylcysteine    O
.    O

Disorders    O
of    O
glycosaminoglycan    B-Polysaccharide114994004
metabolism    O

There    O
is    O
inhibition    O
of    O
the    O
mitotic    O
activity    O
of    O
fibroblasts    O
resulting    O
in    O
reduction    O
of    O
collagen    O
and    O
glycosaminoglycan    B-Polysaccharide114994004
synthesis    O
but    O
probably    O
the    O
earliest    O
evidence    O
of    O
dermal    O
atrophy    O
is    O
a    O
reduction    O
in    O
the    O
diameter    O
of    O
the    O
fibrils    O
and    O
then    O
the    O
collagen    O
bundles    O
become    O
atrophic    O
and    O
separated    O
.    O

Proteic    O
materials    O
,    O
such    O
as    O
collagen    O
or    O
fibrin    O
,    O
and    O
polysaccharidic    O
materials    O
,    O
like    O
chitosan    B-Polysaccharide114994004
or    O
glycosaminoglycan    B-Polysaccharide114994004
(    O
GAGs    O
)    O
,    O
have    O
all    O
proved    O
suitable    O
in    O
terms    O
of    O
cell    O
compatibility    O
,    O
but    O
some    O
issues    O
with    O
potential    O
immunogenicity    O
still    O
remains    O
.    O

An    O
opisthobranch    O
sea    O
slug    O
"    O
Navanax    O
inermis    O
"    O
has    O
chemoreceptors    O
on    O
the    O
sides    O
of    O
its    O
mouth    O
to    O
track    O
mucopolysaccharides    B-Polysaccharide114994004
in    O
the    O
slime    O
trails    O
of    O
prey    O
,    O
and    O
of    O
potential    O
mates    O
.    O

Moreover    O
,    O
the    O
cornea    O
bears    O
more    O
mucopolysaccharide    B-Polysaccharide114994004
(    O
a    O
carbohydrate    O
that    O
has    O
among    O
its    O
repeating    O
units    O
a    O
nitrogenous    O
sugar    O
,    O
hexosamine    O
)    O
to    O
embed    O
the    O
fibrils    O
.    O

The    O
umbilical    O
cord    O
contains    O
Wharton    O
's    O
jelly    O
,    O
a    O
gelatinous    O
substance    O
made    O
largely    O
from    O
mucopolysaccharides    B-Polysaccharide114994004
which    O
protects    O
the    O
blood    O
vessels    O
inside    O
.    O

This    O
selectivity    O
is    O
supposed    O
to    O
be    O
controlled    O
by    O
the    O
type    O
of    O
Glycosaminoglycan    B-Polysaccharide114994004
GAG    O
bonded    O
to    O
the    O
dally    O
protein    O
,    O
considering    O
that    O
there    O
is    O
a    O
huge    O
structural    O
variety    O
in    O
GAGs    O
.    O

These    O
cells    O
are    O
star    O
shaped    O
and    O
synthesize    O
glycosaminoglycan    B-Polysaccharide114994004
.    O

It    O
has    O
a    O
low    O
content    O
of    O
glycosaminoglycans    B-Polysaccharide114994004
(    O
2%    O
of    O
dry    O
weight    O
)    O
.    O

When    O
the    O
surface    O
glycosaminoglycan    B-Polysaccharide114994004
(    O
GAG    O
)    O
layer    O
is    O
damaged    O
(    O
via    O
a    O
urinary    O
tract    O
infection    O
(    O
UTI    O
)    O
,    O
excessive    O
consumption    O
of    O
coffee    O
or    O
sodas    O
,    O
traumatic    O
injury    O
,    O
etc    O
.    O
)    O
,    O
urinary    O
chemicals    O
can    O
"    O
leak    O
"    O
into    O
surrounding    O
tissues    O
,    O
causing    O
pain    O
,    O
inflammation    O
,    O
and    O
urinary    O
symptoms    O
.    O

Here    O
,    O
he    O
did    O
research    O
on    O
glycolipids    O
,    O
glycosaminoglycans    B-Polysaccharide114994004
and    O
glycoproteins    O
and    O
their    O
role    O
in    O
neural    O
development    O
and    O
neurological    O
disorders    O
.    O

On    O
his    O
return    O
to    O
India    O
,    O
he    O
focused    O
his    O
studies    O
on    O
amino    O
acids    O
and    O
inorganic    O
sulphate    O
metabolism    O
,    O
as    O
well    O
as    O
glycosaminoglycan    B-Polysaccharide114994004
.    O

His    O
studies    O
explained    O
the    O
role    O
of    O
glycosaminoglycans    B-Polysaccharide114994004
in    O
neuronal    O
development    O
and    O
the    O
property    O
of    O
glycolipids    O
as    O
biological    O
receptors    O
.    O

The    O
cortical    O
granules    O
contain    O
proteases    O
that    O
clip    O
perivitelline    O
tether    O
proteins    O
,    O
peroxidases    O
that    O
harden    O
the    O
vitelline    O
envelope    O
,    O
and    O
glycosaminoglycans    B-Polysaccharide114994004
that    O
attract    O
water    O
into    O
the    O
perivitelline    O
space    O
,    O
causing    O
it    O
to    O
expand    O
and    O
form    O
the    O
hyaline    O
layer    O
.    O

This    O
layer    O
contains    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
a    O
negatively    O
charged    O
glycosaminoglycan    B-Polysaccharide114994004
that    O
contributes    O
to    O
the    O
electrostatic    O
barrier    O
of    O
the    O
glomerular    O
filter    O
.    O

The    O
end    O
-    O
product    O
of    O
this    O
pathway    O
is    O
UDP    O
-    O
GlcNAc    O
,    O
which    O
is    O
then    O
used    O
for    O
making    O
glycosaminoglycan    B-Polysaccharide114994004
,    O
proteoglycans    B-Polysaccharide114994004
,    O
and    O
glycolipids    O
.    O

The    O
elastic    O
matrix    O
forms    O
lamellae    O
,    O
consisting    O
of    O
elastic    O
fibers    O
,    O
collagens    O
(    O
predominately    O
type    O
III    O
)    O
,    O
proteoglycan    B-Polysaccharide114994004
,    O
and    O
glycoaminoglycan    B-Polysaccharide114994004
.    O

Congenital    O
tracheal    O
collapse    O
appears    O
to    O
be    O
caused    O
by    O
a    O
deficiency    O
of    O
normal    O
components    O
of    O
tracheal    O
ring    O
cartilage    O
like    O
glycosaminoglycan    B-Polysaccharide114994004
,    O
glycoproteins    O
,    O
calcium    O
,    O
and    O
chondroitin    B-Polysaccharide114994004
.    O

This    O
enzyme    O
participates    O
in    O
glycosaminoglycan    B-Polysaccharide114994004
degradation    O
and    O
degradation    O
of    O
glycan    B-Polysaccharide114994004
structures    O
.    O

The    O
more    O
active    O
conformation    O
is    O
thought    O
to    O
be    O
induced    O
when    O
Factor    O
H    O
binds    O
to    O
glycosaminoglycans    B-Polysaccharide114994004
(    O
GAGs    O
)    O
and    O
or    O
sialic    O
acids    O
that    O
are    O
generally    O
present    O
on    O
host    O
cells    O
but    O
not    O
,    O
normally    O
,    O
on    O
pathogen    O
surfaces    O
ensuring    O
that    O
self    O
surfaces    O
are    O
protected    O
whilst    O
complement    O
proceeds    O
unabated    O
on    O
foreign    O
surfaces    O
.    O

Food    O
is    O
enveloped    O
by    O
this    O
part    O
of    O
the    O
gut    O
as    O
it    O
arrives    O
from    O
the    O
foregut    O
by    O
the    O
peritrophic    O
membrane    O
which    O
is    O
a    O
mucopolysaccharide    B-Polysaccharide114994004
layer    O
secreted    O
from    O
the    O
midgut    O
’s    O
epithelial    O
cells    O
.    O

Ardeparin    B-Polysaccharide114994004
(    O
trade    O
name    O
Normiflo    B-Polysaccharide114994004
)    O
is    O
an    O
anticoagulant    O
.    O

Arcitumomab    O
recognizes    O
carcinoembryonic    B-Polysaccharide114994004
antigen    I-Polysaccharide114994004
(    O
CEA    O
)    O
,    O
an    O
antigen    O
over    O
-    O
expressed    O
in    O
95%    O
of    O
colorectal    O
cancers    O
.    O

:*    O
Carcinoembryonic    B-Polysaccharide114994004
antigen    I-Polysaccharide114994004

Another    O
example    O
is    O
carcinoembryonic    B-Polysaccharide114994004
antigen    I-Polysaccharide114994004
,    O
which    O
is    O
elevated    O
in    O
people    O
with    O
colon    O
cancer    O
and    O
other    O
tumors    O
.    O

As    O
Tumor    O
Marker    O
known    O
as    O
AMDL    O
-    O
ELISA    O
DR-70    O
(    O
FDP    O
)    O
and    O
now    O
as    O
Onko    O
-    O
Sure    O
has    O
been    O
approved    O
by    O
US    O
FDA    O
on    O
July    O
1    O
,    O
2008    O
for    O
In    O
vitro    O
diagnostic    O
only    O
and    O
serial    O
testing    O
for    O
monitoring    O
colorectal    O
cancer    O
with    O
more    O
effective    O
by    O
50    O
percent    O
than    O
Carcinoembryonic    B-Polysaccharide114994004
antigen    I-Polysaccharide114994004
(    O
CEA    O
)    O
when    O
CEA    O
values    O
is    O
low    O
.    O

Examples    O
of    O
tumoral    O
markers    O
used    O
to    O
follow    O
up    O
cancer    O
treatment    O
are    O
the    O
Carcinoembryonic    B-Polysaccharide114994004
Antigen    I-Polysaccharide114994004
(    O
CEA    O
)    O
for    O
colorectal    O
cancer    O
and    O
the    O
Prostate    O
Specific    O
Antigen    O
(    O
PSA    O
)    O
for    O
prostate    O
cancer    O
.    O

Cholangiocarcinoma    O
can    O
be    O
detected    O
with    O
these    O
commonly    O
used    O
tumor    O
markers    O
:    O
carbohydrate    O
antigen    O
19    O
-    O
9    O
(    O
CA    O
19    O
-    O
9    O
)    O
,    O
carcinoembryonic    B-Polysaccharide114994004
antigen    I-Polysaccharide114994004
(    O
CEA    O
)    O
and    O
cancer    O
antigen    O
125    O
(    O
CA125    O
)    O
.    O

Parnaparin    B-Polysaccharide114994004
is    O
an    O
antithrombotic    O
and    O
belongs    O
to    O
the    O
group    O
of    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
.    O

Pullulanase    O
(    O
,    O
"    O
limit    O
dextrinase    O
"    O
,    O
"    O
amylopectin    O
6-glucanohydrolase    O
"    O
,    O
"    O
bacterial    O
debranching    O
enzyme    O
"    O
,    O
"    O
debranching    O
enzyme    O
"    O
,    O
"    O
alpha    O
-    O
dextrin    O
endo-1,6-alpha    O
-    O
glucosidase    O
"    O
,    O
"    O
R    O
-    O
enzyme    O
"    O
,    O
"    O
pullulan    O
alpha-1,6-glucanohydrolase    O
"    O
)    O
is    O
a    O
specific    O
kind    O
of    O
glucanase    O
,    O
an    O
amylolytic    O
exoenzyme    O
,    O
that    O
degrades    O
pullulan    B-Polysaccharide114994004
.    O

pullulan    B-Polysaccharide114994004
(    O
"    O
Aureobasidium    O
pullulans    O
"    O
)    O

Palytoxin    O
is    O
an    O
intense    O
vasoconstrictor    O
,    O
and    O
is    O
considered    O
to    O
be    O
one    O
of    O
the    O
most    O
toxic    O
non    O
-    O
protein    O
substances    O
known    O
,    O
second    O
only    O
to    O
maitotoxin    B-Polysaccharide114994004
in    O
terms    O
of    O
toxicity    O
in    O
mice    O
.    O

Maitotoxin    B-Polysaccharide114994004
(    O
or    O
MTX    B-Polysaccharide114994004
)    O
is    O
an    O
extremely    O
potent    O
toxin    O
produced    O
by    O
"    O
Gambierdiscus    O
toxicus    O
"    O
,    O
a    O
dinoflagellate    O
species    O
.    O

curdlan    B-Polysaccharide114994004
(    O
"    O
Alcaligenes    O
faecalis    O
"    O
var    O
.    O
"    O
myxogenes    O
"    O
)    O

"    O
Ingredients    O
"    O
-    O
cereal    O
(    O
whole    O
grain    O
oats    O
,    O
sugar    O
,    O
oat    O
flour    O
,    O
corn    O
syrup    O
,    O
corn    O
starch    O
,    O
salt    O
,    O
trisodium    O
phosphate    O
,    O
color    O
added    O
,    O
natural    O
and    O
artificial    O
flavor    O
,    O
mixed    O
tocopherois    O
)    O
,    O
corn    O
syrup    O
,    O
confectionery    O
coating    O
(    O
sugar    O
,    O
palm    O
kernel    O
oil    O
,    O
maltodextrin    B-Polysaccharide114994004
,    O
yogurt    O
powder    O
(    O
cultured    O
non    O
-    O
fat    O
milk    O
,    O
whey    O
protein    O
concentrate    O
,    O
yogurt    O
cultures    O
)    O
,    O
non    O
-    O
fat    O
milk    O
,    O
soy    O
lecithin    O
,    O
natural    O
flavor    O
)    O
,    O
marshmallows    O
(    O
sugar    O
,    O
modified    O
corn    O
starch    O
,    O
corn    O
syrup    O
,    O
dextrose    O
,    O
gelatin    O
,    O
calcium    O
carbonate    O
,    O
colored    O
with    O
yellow    O
5&6    O
,    O
blue    O
1    O
,    O
red    O
40    O
,    O
artificial    O
flavor    O
)    O
,    O
crisp    O
rice    O
(    O
rice    O
flour    O
,    O
barley    O
malt    O
extract    O
,    O
salt    O
)    O
,    O
canola    O
oil    O
,    O
fructose    O
,    O
high    O
fructose    O
corn    O
syrup    O
,    O
sugar    O
.    O
Contains    O
2%    O
or    O
less    O
of    O
:    O
Glycerin    O
,    O
Maltodextrin    O
,    O
Sorbitol    O
,    O
Water    O
,    O
Gelatin    O
,    O
Salt    O
,    O
Artificial    O
Flavor    O
.    O

Other    O
ingredients    O
can    O
include    O
sweeteners    O
like    O
maltodextrin    B-Polysaccharide114994004
and    O
dextrose    O
,    O
monosodium    O
glutamate    O
(    O
MSG    O
)    O
,    O
disodium    O
inosinate    O
,    O
disodium    O
guanylate    O
,    O
sodium    O
caseinate    O
,    O
modified    O
food    O
starch    O
,    O
monoglyceride    O
and    O
diglyceride    O
,    O
autolyzed    O
yeast    O
extract    O
,    O
natural    O
and    O
artificial    O
flavors    O
,    O
malted    O
barley    O
flour    O
,    O
wheat    O
bran    O
,    O
dried    O
black    O
beans    O
,    O
sour    O
cream    O
,    O
cheddar    O
cheese    O
,    O
etc    O
.    O
;    O
Pringles    O
varieties    O
vary    O
in    O
their    O
ingredients    O
.    O

Maltodextrin    B-Polysaccharide114994004
is    O
a    O
polysaccharide    O
that    O
is    O
used    O
as    O
a    O
food    O
additive    O
.    O

Other    O
ingredients    O
include    O
dicalcium    O
phosphate    O
,    O
microcrystalline    O
cellulose    O
,    O
croscarmellose    O
sodium    O
,    O
stearic    O
acid    O
,    O
film    O
coating    O
(    O
dextrin    O
)    O
,    O
titanium    O
dioxide    O
,    O
hydroxypropylmethyl    B-Polysaccharide114994004
cellulose    I-Polysaccharide114994004
,    O
Brilliant    O
Blue    O
FCF    O
,    O
aluminum    O
lake    O
,    O
Macrogol    O
/    O
PEG    O
8000    O
,    O
dextrose    O
monohydrate    O
,    O
lecithin    O
,    O
maltodextrin    B-Polysaccharide114994004
,    O
Macrogol    O
/    O
PEG    O
400    O
,    O
magnesium    O
stearate    O
,    O
and    O
silica    O
.    O

It    O
is    O
the    O
shortest    O
chain    O
oligosaccharide    O
that    O
can    O
be    O
classified    O
as    O
maltodextrin    B-Polysaccharide114994004
.    O

They    O
include    O
allosteric    O
enzymes    O
that    O
catalyze    O
the    O
production    O
of    O
glucose-1-phosphate    O
from    O
a    O
glucan    B-Polysaccharide114994004
such    O
as    O
glycogen    O
,    O
starch    O
or    O
maltodextrin    B-Polysaccharide114994004
.    O

The    O
plants    O
grow    O
from    O
a    O
fleshy    O
tuberous    O
root    O
which    O
is    O
a    O
source    O
of    O
maltodextrin    B-Polysaccharide114994004
which    O
are    O
used    O
as    O
a    O
sugar    O
substitute    O
.    O

Maltose    O
-    O
binding    O
protein    O
(    O
MBP    O
)    O
is    O
a    O
part    O
of    O
the    O
maltose    O
/    O
maltodextrin    B-Polysaccharide114994004
system    O
of    O
"    O
Escherichia    O
coli    O
"    O
,    O
which    O
is    O
responsible    O
for    O
the    O
uptake    O
and    O
efficient    O
catabolism    O
of    O
maltodextrins    O
.    O

The    O
"    O
malE    O
"    O
gene    O
,    O
coding    O
for    O
MBP    O
,    O
belongs    O
to    O
the    O
Mal    O
regulon    O
of    O
"    O
E.    O
coli    O
"    O
,    O
which    O
consists    O
of    O
ten    O
genes    O
whose    O
products    O
are    O
geared    O
for    O
the    O
efficient    O
uptake    O
and    O
utilization    O
of    O
maltose    O
and    O
maltodextrins    B-Polysaccharide114994004
.    O

The    O
name    O
"    O
biglycan    O
"    O
was    O
proposed    O
in    O
an    O
article    O
by    O
Fisher    O
,    O
Termine    O
and    O
Young    O
in    O
an    O
article    O
in    O
the    O
Journal    O
of    O
Biological    O
Chemistry    O
in    O
1989    O
because    O
the    O
proteoglycan    B-Polysaccharide114994004
contained    O
two    O
GAG    O
chains    O
;    O
formerly    O
it    O
was    O
known    O
as    O
proteoglycan    O
-    O
I    O
(    O
PG    O
-    O
I    O
)    O
.    O

Aggrecanases    O
act    O
on    O
large    O
proteoglycan    B-Polysaccharide114994004
known    O
as    O
aggrecans    O
,    O
which    O
are    O
components    O
of    O
connective    O
tissues    O
such    O
as    O
cartilage    O
.    O

His    O
research    O
has    O
focuses    O
on    O
understanding    O
the    O
structure    O
,    O
biosynthesis    O
and    O
biological    O
roles    O
of    O
proteoglycans    B-Polysaccharide114994004
in    O
mammalian    O
cells    O
and    O
model    O
organisms    O
.    O

The    O
nucleus    O
pulposus    O
consists    O
of    O
large    O
vacuolated    O
notochord    O
cells    O
,    O
small    O
chondrocyte    O
-    O
like    O
cells    O
,    O
collagen    O
fibrils    O
,    O
and    O
aggrecan    O
,    O
a    O
proteoglycan    B-Polysaccharide114994004
that    O
aggregates    O
by    O
binding    O
to    O
hyaluronan    B-Polysaccharide114994004
.    O

Versican    O
is    O
a    O
large    O
extracellular    O
matrix    O
proteoglycan    B-Polysaccharide114994004
that    O
is    O
present    O
in    O
a    O
variety    O
of    O
human    O
tissues    O
.    O

TGFB    O
is    O
a    O
regulatory    O
molecule    O
involved    O
in    O
proteoglycan    B-Polysaccharide114994004
production    O
.    O

Oligodendrocyte    O
precursor    O
cells    O
and    O
C6    O
glioma    O
cells    O
produce    O
metalloproteinase    O
,    O
which    O
is    O
shown    O
to    O
inactivate    O
a    O
type    O
of    O
inhibitory    O
proteoglycan    B-Polysaccharide114994004
secreted    O
by    O
Schwann    O
cells    O
.    O

Often    O
,    O
proteins    O
present    O
in    O
the    O
extracellular    O
space    O
are    O
stored    O
outside    O
the    O
cells    O
by    O
attaching    O
to    O
various    O
extracellular    O
matrix    O
components    O
(    O
Collagens    O
,    O
Proteoglycan    B-Polysaccharide114994004
,    O
etc    O
.    O
)    O
.    O

Homocysteine    O
degrades    O
and    O
inhibits    O
the    O
formation    O
of    O
the    O
three    O
main    O
structural    O
components    O
of    O
arteries    O
:    O
collagen    O
,    O
elastin    O
and    O
proteoglycans    B-Polysaccharide114994004
.    O

Activation    O
of    O
mast    O
cells    O
following    O
engagement    O
of    O
FcεRI    O
results    O
in    O
a    O
process    O
called    O
degranulation    O
,    O
whereby    O
the    O
mast    O
cell    O
releases    O
preformed    O
molecules    O
from    O
its    O
cytoplasmic    O
granules    O
;    O
these    O
are    O
a    O
mixture    O
of    O
compounds    O
including    O
histamine    O
,    O
proteoglycan    B-Polysaccharide114994004
,    O
and    O
serine    O
proteases    O
.    O

Lacritin    O
cell    O
targeting    O
is    O
dependent    O
on    O
the    O
cell    O
surface    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
proteoglycan    B-Polysaccharide114994004
syndecan-1    O
(    O
SDC1    O
)    O
.    O

Histologically    O
,    O
keloids    O
are    O
fibrotic    O
tumors    O
characterized    O
by    O
a    O
collection    O
of    O
atypical    O
fibroblasts    O
with    O
excessive    O
deposition    O
of    O
extracellular    O
matrix    O
components    O
,    O
especially    O
collagen    O
,    O
fibronectin    O
,    O
elastin    O
,    O
and    O
proteoglycan    B-Polysaccharide114994004
.    O

FACIT    O
collagen    O
(    O
Fibril    O
Associated    O
Collagens    O
with    O
Interrupted    O
Triple    O
helices    O
)    O
is    O
a    O
type    O
of    O
collagen    O
which    O
is    O
also    O
a    O
proteoglycan    B-Polysaccharide114994004
.    O

Glycoproteins    O
,    O
proteoglycan    B-Polysaccharide114994004
and    O
glycolipids    O
are    O
the    O
most    O
abundant    O
glycoconjugates    O
found    O
in    O
mammalian    O
cells    O
.    O

Nonmineralized    O
organic    O
component    O
(    O
i.e.    O
type    O
1    O
collagen    O
)    O
,    O
mineralized    O
inorganic    O
component    O
(    O
i.e.    O
hydroxyapatite    O
)    O
,    O
and    O
many    O
other    O
noncollagenous    O
matrix    O
proteins    O
(    O
i.e.    O
glycoproteins    O
and    O
proteoglycan    B-Polysaccharide114994004
)    O
make    O
up    O
the    O
nanocomposite    O
structure    O
of    O
the    O
bone    O
ECM    O
.    O

In    O
the    O
case    O
of    O
Alzheimer    O
's    O
disease    O
,    O
inflammatory    O
processes    O
lead    O
to    O
neuron    O
death    O
by    O
inhibiting    O
growth    O
at    O
axons    O
and    O
activating    O
astrocytes    O
that    O
produce    O
proteoglycans    B-Polysaccharide114994004
.    O

Chondroitinase    O
treatment    O
is    O
a    O
treatment    O
of    O
proteoglycan    B-Polysaccharide114994004
,    O
a    O
protein    O
in    O
the    O
fluid    O
among    O
cells    O
where    O
(    O
among    O
other    O
things    O
)    O
they    O
affect    O
neural    O
activity    O
(    O
communication    O
,    O
plasticity    O
)    O
.    O

Proteoglycan    B-Polysaccharide114994004

Cartilage    O
is    O
composed    O
of    O
cells    O
embedded    O
in    O
an    O
extracellular    O
matrix    O
of    O
collagen    O
fibers    O
and    O
proteoglycans    B-Polysaccharide114994004
.    O

The    O
end    O
-    O
product    O
of    O
this    O
pathway    O
is    O
UDP    O
-    O
GlcNAc    O
,    O
which    O
is    O
then    O
used    O
for    O
making    O
glycosaminoglycan    B-Polysaccharide114994004
,    O
proteoglycans    B-Polysaccharide114994004
,    O
and    O
glycolipids    O
.    O

The    O
elastic    O
matrix    O
forms    O
lamellae    O
,    O
consisting    O
of    O
elastic    O
fibers    O
,    O
collagens    O
(    O
predominately    O
type    O
III    O
)    O
,    O
proteoglycan    B-Polysaccharide114994004
,    O
and    O
glycoaminoglycan    B-Polysaccharide114994004
.    O

Its    O
dry    O
weight    O
is    O
composed    O
of    O
collagen    O
(    O
50%    O
)    O
,    O
non    O
-    O
collagenous    O
glycoproteins    O
(    O
25%    O
)    O
and    O
proteoglycan    B-Polysaccharide114994004
(    O
25%    O
)    O
.    O

Rather    O
,    O
women    O
who    O
are    O
on    O
chronic    O
anticoagulation    O
may    O
be    O
given    O
the    O
option    O
of    O
conversion    O
to    O
either    O
unfractionated    O
heparin    O
or    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
(    O
LMWH    O
)    O
,    O
such    O
as    O
tinzaparin    B-Polysaccharide114994004
,    O
prior    O
to    O
a    O
planned    O
conception    O
.    O

Major    O
side    O
effects    O
of    O
tinzaparin    B-Polysaccharide114994004
are    O
osteoporosis    O
(    O
occurring    O
in    O
up    O
to    O
1%    O
of    O
cases    O
)    O
,    O
thrombocytopenia    O
(    O
heparin    O
-    O
induced    O
thrombocytopenia    O
)    O
,    O
haemorrhage    O
,    O
hair    O
loss    O
and    O
drug    O
allergy    O
.    O

Homopolysaccharides    B-Polysaccharide114994004
are    O
polysaccharides    O
composed    O
of    O
a    O
single    O
type    O
of    O
sugar    O
monomer    O
.    O

Upon    O
investigation    O
of    O
these    O
adverse    O
events    O
by    O
the    O
FDA    O
,    O
academic    O
institutions    O
,    O
and    O
the    O
involved    O
pharmaceutical    O
companies    O
,    O
the    O
contaminant    O
was    O
identified    O
as    O
an    O
"    O
over    O
-    O
sulfated    O
"    O
derivative    O
of    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
a    O
closely    O
related    O
substance    O
obtained    O
from    O
mammal    O
or    O
fish    O
cartilage    O
and    O
often    O
used    O
as    O
a    O
treatment    O
for    O
arthritis    O
.    O

OVDs    O
contain    O
one    O
or    O
more    O
of    O
the    O
following    O
substances    O
in    O
varying    O
concentrations    O
:    O
sodium    B-Polysaccharide114994004
hyaluronate    I-Polysaccharide114994004
,    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
or    O
hydroxypropyl    B-Polysaccharide114994004
methylcellulose    I-Polysaccharide114994004
.    O

Attached    O
to    O
each    O
aggrecan    O
molecule    O
are    O
glycosaminoglycan    O
(    O
GAG    O
)    O
chains    O
of    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
and    O
keratan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
.    O

Other    O
medications    O
have    O
been    O
shown    O
to    O
be    O
useful    O
in    O
topical    O
treatment    O
of    O
refractory    O
ulcers    O
,    O
including    O
glycosaminoglycan    B-Polysaccharide114994004
such    O
as    O
sodium    B-Polysaccharide114994004
hyaluronate    I-Polysaccharide114994004
and    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
aminocaproic    O
acid    O
,    O
and    O
acetylcysteine    O
.    O

Schreckstoff    O
is    O
a    O
mixture    O
,    O
and    O
fragments    O
of    O
a    O
glycosaminoglycan    O
,    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
are    O
able    O
to    O
trigger    O
fear    O
responses    O
.    O

Exposed    O
3-O    O
sulfated    O
group(s    O
)    O
on    O
heparanase    O
-    O
cleaved    O
heparan    O
sulfate    O
(    O
that    O
likely    O
interacts    O
with    O
the    O
cationic    O
face    O
of    O
lacritin    O
's    O
C    O
-    O
terminal    O
amphipathic    O
alpha    O
helix    O
)    O
,    O
and    O
an    O
N    O
-    O
terminal    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
chain    O
(    O
likely    O
also    O
binds    O
to    O
the    O
cationic    O
face    O
)    O
appear    O
to    O
contribute    O
to    O
binding    O
.    O

Chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004

Apolipoprotein    O
O    O
is    O
the    O
first    O
chondroitine    B-Polysaccharide114994004
sulphate    I-Polysaccharide114994004
chain    O
containing    O
apolipoprotein    O
.    O

Xylan    O
is    O
made    O
from    O
units    O
of    O
the    O
pentose    O
sugar    O
xylose    O
,    O
which    O
is    O
known    O
for    O
being    O
the    O
first    O
saccharide    O
in    O
multiple    O
biosynthetic    O
pathways    O
of    O
anionic    O
polysaccharides    O
such    O
as    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
and    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
.    O

This    O
enzyme    O
participates    O
in    O
the    O
biosynthesis    O
of    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
and    O
glycan    B-Polysaccharide114994004
structures    O
.    O

Phosphated    O
distarch    O
phosphate    O
,    O
is    O
a    O
modified    O
resistant    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
.    O

Carbohydrates    O
not    O
digested    O
in    O
the    O
small    O
intestine    O
,    O
including    O
resistant    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
foods    O
such    O
as    O
potato    O
,    O
bean    O
,    O
oat    O
,    O
wheat    O
flour    O
,    O
and    O
several    O
monosaccharide    O
oligosaccharides    O
and    O
starch    O
,    O
are    O
digested    O
in    O
a    O
variable    O
when    O
they    O
reach    O
the    O
large    O
intestine    O
.    O

The    O
remaining    O
65%    O
of    O
the    O
starch    O
is    O
a    O
resistant    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
classified    O
as    O
RS1    O
.    O

In    O
general    O
,    O
foods    O
with    O
higher    O
amounts    O
of    O
fiber    O
and/or    O
resistant    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
have    O
a    O
lower    O
glycemic    O
response    O
.    O

Hydroxypropyl    O
distarch    O
phosphate    O
(    O
HDP    O
)    O
is    O
a    O
modified    O
resistant    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
.    O

DEAE-Sepharose    B-Polysaccharide114994004
,    O
DEAE-650    O
and    O
DEAE    O
-    O
Sephadex    O
are    O
commonly    O
used    O
in    O
chromatography    O
.    O

Due    O
to    O
their    O
biodegradative    O
and    O
biosynthetic    O
capabilities    O
,    O
sphingomonads    O
have    O
been    O
used    O
for    O
a    O
wide    O
range    O
of    O
biotechnological    O
applications    O
,    O
from    O
bioremediation    O
of    O
environmental    O
contaminants    O
to    O
production    O
of    O
extracellular    O
polymers    O
such    O
as    O
sphingans    O
(    O
e.g.    O
,    O
gellan    O
,    O
welan    B-Polysaccharide114994004
,    O
and    O
rhamsan    O
)    O
used    O
extensively    O
in    O
the    O
food    O
and    O
other    O
industries    O
.    O

Iodine    O
is    O
used    O
in    O
the    O
presence    O
of    O
a    O
starch    B-Polysaccharide114994004
indicator    I-Polysaccharide114994004
.    O

Persipan    O
often    O
contains    O
0.5%    O
starch    O
so    O
that    O
it    O
can    O
be    O
easily    O
differentiated    O
from    O
marzipan    O
with    O
an    O
iodine    B-Polysaccharide114994004
test    I-Polysaccharide114994004
.    O

Mucigel    B-Polysaccharide114994004
-    O
substance    O
that    O
creates    O
symbiotic    O
environment    O
for    O
fungi    O

In    O
2007    O
,    O
the    O
Royal    O
Society    O
of    O
Chemistry    O
Malcolm    O
Campbell    O
Memorial    O
Prize    O
was    O
awarded    O
to    O
researchers    O
for    O
its    O
work    O
on    O
a    O
new    O
anaesthesia    O
drug    O
,    O
sugammadex    B-Polysaccharide114994004
.    O

In    O
another    O
major    O
advance    O
the    O
reversal    O
agent    O
sugammadex    B-Polysaccharide114994004
was    O
the    O
first    O
selective    O
relaxant    O
binding    O
agent    O
(    O
SRBA    O
)    O
for    O
Neuromuscular    O
Block    O
Reversal    O
to    O
be    O
identified    O
,    O
and    O
has    O
recently    O
entered    O
the    O
market    O
in    O
Europe    O
.    O

This    O
effect    O
–    O
presumably    O
caused    O
by    O
the    O
polysaccharide    O
,    O
lentinan    B-Polysaccharide114994004
–    O
is    O
more    O
common    O
in    O
Asia    O
but    O
may    O
be    O
growing    O
in    O
occurrence    O
in    O
Europe    O
as    O
shiitake    O
consumption    O
increases    O
.    O

File    O
:    O
Lentinan    B-Polysaccharide114994004
,    O
a    O
beta    O
-    O
glucan    O
isolated    O
from    O
the    O
shiitake    O
mushroom    O

These    O
microfibrils    B-Polysaccharide114994004
are    O
made    O
on    O
the    O
surface    O
of    O
cell    O
membranes    O
to    O
reinforce    O
cells    O
walls    O
,    O
which    O
has    O
been    O
researched    O
extensively    O
by    O
plant    O
biochemists    O
and    O
cell    O
biologist    O
because    O
1    O
)    O
they    O
regulate    O
cellular    O
morphogenesis    O
and    O
2    O
)    O
they    O
serve    O
alongside    O
many    O
other    O
constituents    O
(    O
i.e.    O
lignin    O
,    O
hemicellulose    B-Polysaccharide114994004
,    O
pectin    O
)    O
in    O
the    O
cell    O
wall    O
as    O
a    O
strong    O
structural    O
support    O
and    O
cell    O
shape    O
.    O

Microfibrils    B-Polysaccharide114994004
are    O
cross    O
-    O
linked    O
together    O
by    O
hemicellulose    O
homopolymers    O
.    O

Spiral    O
coils    O
,    O
formed    O
of    O
helicoidally    O
stacked    O
cellulose    O
microfibrils    B-Polysaccharide114994004
,    O
create    O
Bragg    O
reflection    O
in    O
the    O
"    O
marble    O
berries    O
"    O
of    O
the    O
African    O
herb    O
"    O
Pollia    O
condensata    O
"    O
,    O
resulting    O
in    O
the    O
most    O
intense    O
blue    O
coloration    O
known    O
in    O
nature    O
.    O

Within    O
the    O
cell    O
wall    O
,    O
this    O
expansion    O
of    O
surface    O
area    O
involves    O
slippage    O
or    O
movement    O
of    O
cellulose    O
microfibril    B-Polysaccharide114994004
,    O
which    O
normally    O
is    O
coupled    O
to    O
simultaneous    O
uptake    O
of    O
water    O
.    O

Attached    O
to    O
each    O
aggrecan    O
molecule    O
are    O
glycosaminoglycan    O
(    O
GAG    O
)    O
chains    O
of    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
and    O
keratan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
.    O

:    O
Hydrolysis    O
of    O
the    O
6-sulfate    O
groups    O
of    O
the    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosamine    O
6-sulfate    O
units    O
of    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
and    O
keratan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004

It    O
is    O
involved    O
in    O
the    O
catabolism    O
of    O
heparin    O
,    O
heparan    B-Polysaccharide114994004
sulphate    I-Polysaccharide114994004
,    O
and    O
keratan    B-Polysaccharide114994004
sulphate    I-Polysaccharide114994004
.    O

Once    O
settled    O
in    O
the    O
stroma    O
,    O
keratocytes    O
start    O
synthesizing    O
collagen    O
molecules    O
of    O
different    O
types    O
(    O
I    O
,    O
V    O
,    O
VI    O
)    O
and    O
keratan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
.    O

In    O
enzymology    O
,    O
a    O
xyloglucan    O
:    O
xyloglucosyl    O
transferase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
chemical    O
reaction    O
in    O
which    O
a    O
beta-(1,4    O
)    O
bond    O
in    O
the    O
backbone    O
of    O
a    O
xyloglucan    B-Polysaccharide114994004
in    O
broken    O
;    O
the    O
xyloglucanyl    O
segment    O
is    O
then    O
transferred    O
to    O
the    O
O4    O
of    O
the    O
non    O
-    O
reducing    O
terminal    O
glucose    O
residue    O
of    O
either    O
xyloglucan    O
or    O
an    O
oligosaccharide    O
thereof    O
.    O

An    O
example    O
of    O
this    O
is    O
that    O
secondary    O
wall    O
in    O
wood    O
contain    O
polysaccharides    O
called    O
xylan    B-Polysaccharide114994004
,    O
whereas    O
the    O
primary    O
wall    O
contains    O
the    O
polysaccharide    O
xyloglucan    B-Polysaccharide114994004
.    O

Semuloparin    B-Polysaccharide114994004
(    O
INN    O
,    O
USAN    O
)    O
is    O
an    O
experimental    O
antithrombotic    O
being    O
developed    O
by    O
Sanofi    O
-    O
Aventis    O
and    O
belongs    O
to    O
the    O
group    O
of    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
(    O
LMWH    O
)    O
.    O

These    O
bacteria    O
lack    O
peptidoglycan    B-Polysaccharide114994004
in    O
their    O
cell    O
wall    O
and    O
have    O
a    O
compartmentalized    O
cytoplasm    O
.    O

As    O
with    O
all    O
other    O
organisms    O
within    O
the    O
order    O
Planctomycetes    O
,    O
the    O
cell    O
wall    O
does    O
not    O
contain    O
peptidoglycan    B-Polysaccharide114994004
.    O

The    O
muralytic    O
(    O
peptidoglycan    B-Polysaccharide114994004
-    O
digesting    O
)    O
enzyme    O
,    O
P5    O
,    O
then    O
digests    O
a    O
portion    O
of    O
the    O
cell    O
wall    O
,    O
and    O
the    O
nucleocapsid    O
enters    O
the    O
cell    O
coated    O
with    O
the    O
bacterial    O
outer    O
membrane    O
.    O

OBPgp279    O
is    O
an    O
endolysin    O
that    O
hydrolyzes    O
peptidoglycan    B-Polysaccharide114994004
,    O
a    O
major    O
constituent    O
in    O
bacterial    O
membrane    O
.    O

It    O
is    O
bactericidal    O
and    O
acts    O
by    O
inhibiting    O
synthesis    O
of    O
the    O
peptidoglycan    B-Polysaccharide114994004
layer    O
of    O
the    O
bacterial    O
cell    O
wall    O
.    O

This    O
penetration    O
mechanism    O
can    O
involve    O
electrochemical    O
membrane    O
potential    O
,    O
ATP    O
molecules    O
,    O
enzymatic    O
splitting    O
of    O
peptidoglycan    B-Polysaccharide114994004
layer    O
,    O
or    O
all    O
three    O
of    O
these    O
factor    O
can    O
be    O
vital    O
for    O
the    O
penetration    O
of    O
the    O
nucleic    O
acid    O
inside    O
the    O
bacterial    O
cell    O
.    O

This    O
layered    O
structure    O
is    O
called    O
peptidoglycan    B-Polysaccharide114994004
.    O

D    O
-    O
glutamate    O
is    O
a    O
monomer    O
of    O
the    O
peptidoglycan    B-Polysaccharide114994004
layer    O
in    O
prokaryotic    O
cell    O
walls    O
.    O

Its    O
composition    O
is    O
distinct    O
from    O
that    O
of    O
the    O
inner    O
cytoplasmic    O
cell    O
membrane    O
-    O
among    O
other    O
things    O
,    O
the    O
outer    O
leaflet    O
of    O
the    O
outer    O
membrane    O
of    O
many    O
gram    O
-    O
negative    O
bacteria    O
includes    O
a    O
complex    O
lipopolysaccharide    O
whose    O
lipid    O
portion    O
acts    O
as    O
an    O
endotoxin    O
-    O
and    O
in    O
some    O
bacteria    O
such    O
as    O
"    O
E.    O
coli    O
"    O
it    O
is    O
linked    O
to    O
the    O
cell    O
's    O
peptidoglycan    B-Polysaccharide114994004
by    O
Braun    O
's    O
lipoprotein    O
.    O

Assignment    O
of    O
a    O
strain    O
to    O
the    O
genus    O
"    O
Staphylococcus    O
"    O
requires    O
it    O
to    O
be    O
a    O
Gram    O
-    O
positive    O
coccus    O
that    O
forms    O
clusters    O
,    O
produces    O
catalase    O
,    O
has    O
an    O
appropriate    O
cell    O
wall    O
structure    O
(    O
including    O
peptidoglycan    B-Polysaccharide114994004
type    O
and    O
teichoic    O
acid    O
presence    O
)    O
and    O
G    O
+    O
C    O
content    O
of    O
DNA    O
in    O
a    O
range    O
of    O
30–40    O
mol%    O
.    O

It    O
inhibits    O
cross    O
-    O
linkage    O
between    O
the    O
linear    O
peptidoglycan    B-Polysaccharide114994004
polymer    O
chains    O
that    O
make    O
up    O
a    O
major    O
component    O
of    O
the    O
cell    O
wall    O
of    O
Gram    O
-    O
positive    O
bacteria    O
.    O

The    O
holin    O
pores    O
are    O
generally    O
stable    O
and    O
nonspecific    O
,    O
allowing    O
endolysin    O
access    O
to    O
the    O
peptidoglycan    B-Polysaccharide114994004
.    O

[    O
A    O
]    O
Gram    O
-    O
negative    O
with    O
a    O
peptidoglycan    B-Polysaccharide114994004
cell    O
wall    O
like    O
Chlorosome    O
.    O

[    O
H    O
]    O
Gram    O
-    O
positive    O
Bacteria    O
:    O
hypertrophy    O
of    O
the    O
wall    O
peptidoglycan    B-Polysaccharide114994004
,    O
sortasa    O
enzyme    O
and    O
a    O
loss    O
of    O
the    O
outer    O
membrane    O
.    O

[    O
K    O
]    O
Neomura    O
revolution    O
:    O
Replacement    O
of    O
peptidoglycan    B-Polysaccharide114994004
by    O
glycoproteins    O
and    O
lipoproteins    O
.    O

It    O
has    O
the    O
ability    O
to    O
degrade    O
peptidoglycan    B-Polysaccharide114994004
.    O

As    O
a    O
cyclic    O
analogue    O
of    O
D    O
-    O
alanine    O
,    O
cycloserine    O
acts    O
against    O
two    O
crucial    O
enzymes    O
important    O
in    O
the    O
cytosolic    O
stages    O
of    O
peptidoglycan    B-Polysaccharide114994004
synthesis    O
:    O
alanine    O
racemase    O
(    O
Alr    O
)    O
and    O
D    O
-    O
alanine    O
:    O
D    O
-    O
alanine    O
ligase    O
(    O
Ddl    O
)    O
.    O

Holins    O
form    O
pores    O
in    O
the    O
host    O
's    O
cell    O
membrane    O
,    O
allowing    O
lysins    O
to    O
reach    O
and    O
degrade    O
peptidoglycan    B-Polysaccharide114994004
,    O
a    O
component    O
of    O
bacterial    O
cell    O
walls    O
.    O

The    O
conversion    O
of    O
prophenoloxidase    O
to    O
the    O
active    O
form    O
of    O
the    O
enzyme    O
can    O
be    O
brought    O
about    O
by    O
minuscule    O
amounts    O
of    O
molecules    O
such    O
as    O
lipopolysaccharide    O
,    O
peptidoglycan    B-Polysaccharide114994004
and    O
glucan    B-Polysaccharide114994004
from    O
microorganisms    O
.    O

In    O
these    O
microorganisms    O
,    O
D    O
-    O
amino    O
acids    O
are    O
part    O
of    O
peptidoglycan    B-Polysaccharide114994004
(    O
a    O
major    O
component    O
of    O
the    O
bacterial    O
cell    O
wall    O
)    O
.    O

This    O
enzyme    O
participates    O
in    O
peptidoglycan    B-Polysaccharide114994004
biosynthesis    O
.    O

The    O
peptidoglycan    B-Polysaccharide114994004
layer    O
gives    O
the    O
cell    O
wall    O
its    O
strength    O
,    O
and    O
helps    O
maintain    O
the    O
overall    O
shape    O
of    O
the    O
cell    O
.    O

Its    O
cell    O
wall    O
peptidoglycan    B-Polysaccharide114994004
is    O
similar    O
to    O
the    O
L    O
-    O
Lys    O
-    O
Gly3    O
-    O
5    O
L    O
-    O
Ser0.6    O
-    O
1.5    O
type    O
found    O
in    O
predominantly    O
human    O
species    O
.    O

Gram    O
-    O
positive    O
bacteria    O
have    O
a    O
thick    O
peptidoglycan    B-Polysaccharide114994004
layer    O
in    O
their    O
cell    O
wall    O
,    O
which    O
retains    O
the    O
crystal    O
violet    O
during    O
Gram    O
staining    O
,    O
resulting    O
in    O
a    O
purple    O
color    O
.    O

Ceftriaxone    O
selectively    O
and    O
irreversibly    O
inhibits    O
bacterial    O
cell    O
wall    O
synthesis    O
by    O
binding    O
to    O
transpeptidases    O
,    O
also    O
called    O
transamidases    O
,    O
which    O
are    O
penicillin    O
-    O
binding    O
proteins    O
(    O
PBPs    O
)    O
that    O
catalyze    O
the    O
cross    O
-    O
linking    O
of    O
the    O
peptidoglycan    B-Polysaccharide114994004
polymers    O
forming    O
the    O
bacterial    O
cell    O
wall    O
.    O

The    O
peptidoglycan    B-Polysaccharide114994004
cross    O
-    O
linking    O
activity    O
of    O
PBPs    O
is    O
a    O
construction    O
and    O
repair    O
mechanism    O
that    O
normally    O
helps    O
to    O
maintain    O
bacterial    O
cell    O
wall    O
integrity    O
,    O
so    O
the    O
inhibition    O
of    O
PBPs    O
leads    O
to    O
damage    O
and    O
destruction    O
of    O
the    O
cell    O
wall    O
and    O
eventually    O
to    O
cell    O
lysis    O
.    O

The    O
cyst    O
walls    O
of    O
bacteria    O
are    O
formed    O
by    O
the    O
thickening    O
of    O
the    O
normal    O
cell    O
wall    O
with    O
added    O
peptidoglycan    B-Polysaccharide114994004
layers    O
whereas    O
the    O
walls    O
of    O
protozoan    O
cysts    O
are    O
made    O
of    O
chitin    O
,    O
a    O
type    O
of    O
glycopolymer    O
.    O

Beta    O
glucans    O
are    O
carbohydrate    O
polymers    O
that    O
are    O
cross    O
-    O
linked    O
with    O
other    O
fungal    O
cell    O
wall    O
components    O
(    O
The    O
bacterial    O
equivalent    O
is    O
peptidoglycan    B-Polysaccharide114994004
)    O
.    O

Ticarcillin    O
's    O
antibiotic    O
properties    O
arise    O
from    O
its    O
ability    O
to    O
prevent    O
cross    O
-    O
linking    O
of    O
peptidoglycan    B-Polysaccharide114994004
during    O
cell    O
wall    O
synthesis    O
,    O
when    O
the    O
bacteria    O
try    O
to    O
divide    O
,    O
causing    O
cell    O
death    O
.    O

Oxidized    B-Polysaccharide114994004
cellulose    I-Polysaccharide114994004
is    O
a    O
water    O
-    O
insoluble    O
derivative    O
of    O
cellulose    O
.    O

Long    O
before    O
a    O
deeper    O
understanding    O
of    O
their    O
numerous    O
biological    O
functions    O
,    O
the    O
plant    O
lectins    O
,    O
also    O
known    O
as    O
phytohemagglutinins    O
,    O
were    O
noted    O
for    O
their    O
particular    O
high    O
specificity    O
for    O
foreign    O
glycoconjugate    B-Polysaccharide114994004
(    O
e.g.    O
those    O
of    O
fungi    O
,    O
invertebrates    O
,    O
and    O
animals    O
)    O
and    O
used    O
in    O
biomedicine    O
for    O
blood    O
cell    O
testing    O
and    O
in    O
biochemistry    O
for    O
fractionation    O
.    O

They    O
typically    O
agglutinate    O
certain    O
animal    O
cells    O
and/or    O
precipitate    O
glycoconjugate    B-Polysaccharide114994004
.    O

The    O
two    O
molecular    O
groups    O
form    O
a    O
glycoconjugate    B-Polysaccharide114994004
through    O
a    O
glycosidic    O
bond    O
,    O
a    O
type    O
of    O
covalent    O
bond    O
.    O

In    O
enzymology    O
,    O
a    O
cellodextrin    B-Polysaccharide114994004
phosphorylase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
chemical    O
reaction    O

It    O
works    O
by    O
targeting    O
the    O
glucan    B-Polysaccharide114994004
in    O
fungal    O
cell    O
walls    O
.    O

The    O
conversion    O
of    O
prophenoloxidase    O
to    O
the    O
active    O
form    O
of    O
the    O
enzyme    O
can    O
be    O
brought    O
about    O
by    O
minuscule    O
amounts    O
of    O
molecules    O
such    O
as    O
lipopolysaccharide    O
,    O
peptidoglycan    B-Polysaccharide114994004
and    O
glucan    B-Polysaccharide114994004
from    O
microorganisms    O
.    O

In    O
enzymology    O
,    O
an    O
oligosaccharide    O
4-alpha    O
-    O
D    O
-    O
glucosyltransferase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
chemical    O
reaction    O
in    O
which    O
the    O
non    O
-    O
reducing    O
terminal    O
alpha    O
-    O
D    O
-    O
glucose    O
residue    O
is    O
transferred    O
from    O
a    O
1,4-alpha    O
-    O
D    O
-    O
glucan    B-Polysaccharide114994004
to    O
the    O
4-position    O
of    O
an    O
alpha    O
-    O
D    O
-    O
glucan    O
.    O

They    O
include    O
allosteric    O
enzymes    O
that    O
catalyze    O
the    O
production    O
of    O
glucose-1-phosphate    O
from    O
a    O
glucan    B-Polysaccharide114994004
such    O
as    O
glycogen    O
,    O
starch    O
or    O
maltodextrin    B-Polysaccharide114994004
.    O

Enzymes    O
that    O
break    O
down    O
glucan    B-Polysaccharide114994004
by    O
removing    O
a    O
glucose    O
residue    O
(    O
break    O
"    O
O    O
"-    O
glycosidic    O
bond    O
)    O

In    O
the    O
case    O
of    O
"    O
Lactobacillus    O
"    O
,    O
some    O
of    O
these    O
saccharides    O
may    O
be    O
glucan    B-Polysaccharide114994004
that    O
can    O
be    O
synthesized    O
from    O
glucose    O
present    O
in    O
the    O
wine    O
as    O
low    O
as    O
50–100    O
mg    O
/    O
l    O
(    O
0.005    O
to    O
0.01%    O
residual    O
sugar    O
)    O
and    O
afflict    O
seemingly    O
"    O
dry    O
"    O
wines    O
.    O

Lafora    O
disease    O
is    O
a    O
rare    O
genetic    O
disorder    O
marked    O
by    O
the    O
presence    O
of    O
abnormal    O
polyglucosan    B-Polysaccharide114994004
deposits    O
.    O

Echinocandins    O
are    O
a    O
new    O
class    O
of    O
antifungal    O
drugs    O
that    O
inhibit    O
the    O
synthesis    O
of    O
glucan    B-Polysaccharide114994004
in    O
the    O
cell    O
wall    O
,    O
via    O
noncompetitive    O
inhibition    O
of    O
the    O
enzyme    O
1,3-β    O
glucan    O
synthase    O
and    O
are    O
thus    O
called    O
"    O
penicillin    O
of    O
antifungals    O
"    O
(    O
a    O
property    O
shared    O
with    O
papulacandins    O
)    O
as    O
penicillin    O
has    O
a    O
similar    O
mechanism    O
against    O
bacteria    O
but    O
not    O
fungi    O
.    O

It    O
has    O
been    O
shown    O
that    O
in    O
the    O
case    O
of    O
GDNF    O
,    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
glycosaminoglycan    B-Polysaccharide114994004
are    O
also    O
required    O
to    O
be    O
present    O
at    O
the    O
cell    O
surface    O
in    O
order    O
for    O
RET    O
mediated    O
GDNF    O
signalling    O
to    O
occur    O
.    O

HBV    O
initially    O
binds    O
to    O
heparin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
proteoglycan    I-Polysaccharide114994004
.    O

In    O
the    O
case    O
of    O
a    O
herpes    O
virus    O
,    O
initial    O
interactions    O
occur    O
when    O
two    O
viral    O
envelope    O
glycoprotein    O
called    O
glycoprotein    O
C    O
(    O
gC    O
)    O
and    O
glycoprotein    O
B    O
(    O
gB    O
)    O
bind    O
to    O
a    O
cell    O
surface    O
particle    O
called    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
.    O

He    O
discovered    O
the    O
dependence    O
of    O
tumor    O
formation    O
on    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
the    O
first    O
small    O
molecule    O
inhibitors    O
of    O
heparan    O
sulfate    O
,    O
the    O
action    O
of    O
proteoglycans    O
as    O
receptors    O
for    O
hepatic    O
lipoprotein    O
clearance    O
and    O
for    O
delivery    O
of    O
therapeutic    O
agents    O
.    O

Esko    O
’s    O
work    O
has    O
focused    O
on    O
the    O
structure    O
,    O
assembly    O
and    O
function    O
of    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
proteoglycans    O
for    O
the    O
last    O
30    O
years    O
.    O

This    O
includes    O
development    O
of    O
animal    O
models    O
lacking    O
key    O
enzymes    O
involved    O
in    O
proteoglycan    O
assembly    O
;    O
application    O
of    O
genome    O
-    O
wide    O
methods    O
to    O
identify    O
novel    O
genes    O
involved    O
in    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
assembly    O
;    O
analysis    O
of    O
guanidinylated    O
glycosides    O
that    O
bind    O
to    O
proteoglycans    O
;    O
studies    O
of    O
proteoglycans    O
in    O
lipoprotein    O
metabolism    O
in    O
the    O
liver    O
and    O
macrophages    O
;    O
and    O
studies    O
of    O
proteoglycan    O
-    O
associated    O
receptors    O
with    O
particular    O
emphasis    O
on    O
the    O
vasculature    O
and    O
inflammation    O
.    O

:    O
Hydrolysis    O
of    O
the    O
6-sulfate    O
groups    O
of    O
the    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosamine    O
6-sulfate    O
units    O
of    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
and    O
keratan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004

It    O
is    O
involved    O
in    O
the    O
catabolism    O
of    O
heparin    O
,    O
heparan    B-Polysaccharide114994004
sulphate    I-Polysaccharide114994004
,    O
and    O
keratan    B-Polysaccharide114994004
sulphate    I-Polysaccharide114994004
.    O

Lacritin    O
cell    O
targeting    O
is    O
dependent    O
on    O
the    O
cell    O
surface    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
proteoglycan    B-Polysaccharide114994004
syndecan-1    O
(    O
SDC1    O
)    O
.    O

Syndecan-1    O
binds    O
many    O
growth    O
factors    O
through    O
its    O
long    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
side    O
-    O
chains    O
.    O

This    O
layer    O
contains    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
a    O
negatively    O
charged    O
glycosaminoglycan    B-Polysaccharide114994004
that    O
contributes    O
to    O
the    O
electrostatic    O
barrier    O
of    O
the    O
glomerular    O
filter    O
.    O

Xylan    O
is    O
made    O
from    O
units    O
of    O
the    O
pentose    O
sugar    O
xylose    O
,    O
which    O
is    O
known    O
for    O
being    O
the    O
first    O
saccharide    O
in    O
multiple    O
biosynthetic    O
pathways    O
of    O
anionic    O
polysaccharides    O
such    O
as    O
heparan    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
and    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
.    O

This    O
process    O
is    O
initiated    O
by    O
polyarginines    O
interacting    O
with    O
heparan    B-Polysaccharide114994004
sulphate    I-Polysaccharide114994004
that    O
promote    O
endocytosis    O
.    O

Paramylon    B-Polysaccharide114994004
is    O
a    O
carbohydrate    O
similar    O
to    O
starch    O
.    O

Her    O
biggest    O
success    O
was    O
the    O
win    O
of    O
the    O
bronze    O
medal    O
in    O
the    O
15    O
km    O
at    O
the    O
2001    O
FIS    O
Nordic    O
World    O
Ski    O
Championships    O
,    O
but    O
she    O
is    O
better    O
known    O
for    O
her    O
doping    O
controversies    O
at    O
those    O
championships    O
:    O
Varis    O
was    O
part    O
of    O
the    O
4×5    O
km    O
relay    O
that    O
was    O
disqualified    O
when    O
fellow    O
skiers    O
Virpi    O
Kuitunen    O
and    O
Milla    O
Jauho    O
were    O
disqualified    O
for    O
taking    O
hydroxyethyl    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
,    O
a    O
banned    O
blood    O
plasma    O
expander    O
.    O

He    O
was    O
on    O
his    O
way    O
to    O
become    O
one    O
of    O
the    O
greatest    O
stars    O
in    O
cross    O
-    O
country    O
skiing    O
history    O
,    O
until    O
he    O
was    O
caught    O
doping    O
in    O
the    O
Finnish    O
2001    O
FIS    O
Nordic    O
World    O
Ski    O
Championships    O
scandal    O
for    O
taking    O
hydroxyethyl    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
(    O
HES    O
)    O
,    O
a    O
blood    O
plasma    O
expander    O
usually    O
used    O
to    O
cover    O
up    O
the    O
use    O
of    O
erythropoietin    O
(    O
EPO    O
)    O
in    O
athletes    O
.    O

Anti    O
-    O
doping    O
tests    O
at    O
the    O
2001    O
World    O
Nordic    O
skiing    O
championships    O
in    O
Lahti    O
,    O
Finland    O
revealed    O
that    O
Jari    O
Isometsä    O
,    O
Janne    O
Immonen    O
and    O
two    O
other    O
skiers    O
from    O
Finland    O
's    O
gold    O
-    O
medal    O
relay    O
team    O
,    O
Mika    O
Myllylä    O
and    O
Harri    O
Kirvesniemi    O
,    O
and    O
two    O
female    O
skiers    O
tested    O
positive    O
for    O
hydroxyethyl    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
(    O
HES    O
)    O
,    O
a    O
blood    O
plasma    O
expander    O
usually    O
used    O
to    O
cover    O
up    O
the    O
use    O
of    O
erythropoietin    O
(    O
EPO    O
)    O
.    O

Peter    O
Velits    O
was    O
classified    O
second    O
at    O
the    O
2010    O
Vuelta    O
a    O
España    O
after    O
initial    O
runner    O
-    O
up    O
Ezequiel    O
Mosquera    O
was    O
disqualified    O
for    O
a    O
positive    O
test    O
for    O
Hydroxyethyl    B-Polysaccharide114994004
starch    I-Polysaccharide114994004
.    O

Urgent    O
medical    O
attention    O
in    O
this    O
phase    O
consists    O
of    O
fluid    O
resuscitation    O
efforts    O
,    O
mainly    O
the    O
intravenous    O
administration    O
of    O
saline    O
solution    O
plus    O
hetastarch    B-Polysaccharide114994004
or    O
albumin    O
and    O
colloids    O
(    O
to    O
increase    O
the    O
remaining    O
blood    O
flow    O
to    O
vital    O
organs    O
like    O
the    O
kidneys    O
)    O
,    O
as    O
well    O
as    O
glucocorticoids    O
(    O
steroids    O
like    O
methylprednisolone    O
,    O
to    O
reduce    O
or    O
stop    O
the    O
capillary    O
leak    O
)    O
.    O

Japonica    O
rice    O
is    O
also    O
stickier    O
due    O
to    O
the    O
higher    O
content    O
of    O
amylopectin    B-Polysaccharide114994004
,    O
whereas    O
Indica    O
rice    O
starch    O
consists    O
of    O
less    O
amylopectin    O
and    O
more    O
amylose    B-Polysaccharide114994004
.    O

It    O
has    O
short    O
grains    O
due    O
to    O
the    O
presence    O
of    O
amylopectin    B-Polysaccharide114994004
.    O

Water    O
then    O
enters    O
via    O
amorphous    O
regions    O
the    O
tightly    O
bound    O
areas    O
of    O
double    O
helical    O
structures    O
of    O
amylopectin    B-Polysaccharide114994004
.    O

amylopectin    B-Polysaccharide114994004

Glutinous    O
rice    O
is    O
distinguished    O
from    O
other    O
types    O
of    O
rice    O
by    O
having    O
no    O
(    O
or    O
negligible    O
amounts    O
of    O
)    O
amylose    B-Polysaccharide114994004
,    O
and    O
high    O
amounts    O
of    O
amylopectin    B-Polysaccharide114994004
(    O
the    O
two    O
components    O
of    O
starch    O
)    O
.    O

It    O
is    O
found    O
in    O
grains    O
or    O
granules    O
in    O
the    O
cell    O
's    O
cytoplasm    O
and    O
is    O
composed    O
of    O
an    O
α-linked    B-Polysaccharide114994004
glucose    O
polymer    O
with    O
a    O
degree    O
of    O
branching    O
intermediate    O
between    O
amylopectin    B-Polysaccharide114994004
and    O
glycogen    O
,    O
though    O
more    O
similar    O
to    O
the    O
former    O
.    O

The    O
structure    O
of    O
floridean    O
starch    O
polymers    O
is    O
most    O
similar    O
to    O
amylopectin    B-Polysaccharide114994004
and    O
is    O
sometimes    O
described    O
as    O
"    O
semi    O
-    O
amylopectin    O
"    O
.    O

Floridean    O
starch    O
is    O
often    O
described    O
in    O
contrast    O
to    O
starch    O
(    O
a    O
mixture    O
of    O
amylopectin    B-Polysaccharide114994004
and    O
amylose    B-Polysaccharide114994004
)    O
and    O
glycogen    O
:    O

There    O
are    O
several    O
different    O
types    O
of    O
carbohydrates    O
:    O
polysaccharides    O
(    O
e.g.    O
,    O
starch    O
,    O
amylopectin    B-Polysaccharide114994004
,    O
glycogen    O
,    O
cellulose    O
)    O
,    O
monosaccharides    O
(    O
e.g.    O
,    O
glucose    O
,    O
galactose    O
,    O
fructose    O
,    O
ribose    O
)    O
and    O
the    O
disaccharides    O
(    O
e.g.    O
,    O
sucrose    O
,    O
maltose    O
,    O
lactose    O
)    O
.    O

Mice    O
treated    O
with    O
the    O
prebiotic    B-Polysaccharide114994004
oligofructose    B-Polysaccharide114994004
showed    O
improved    O
intestinal    O
homeostasis    O
as    O
indicated    O
by    O
increased    O
intectin    O
.    O

Because    O
of    O
the    O
caloric    O
reduction    O
,    O
lower    O
fat    O
content    O
,    O
dramatic    O
fiber    O
increase    O
and    O
prebiotic    B-Polysaccharide114994004
tendencies    O
of    O
the    O
replacement    O
inulin    O
,    O
these    O
breads    O
are    O
considered    O
a    O
healthier    O
alternative    O
to    O
traditionally    O
prepared    O
leavening    O
breads    O
.    O

Prebiotic    B-Polysaccharide114994004
(nutrition)    I-Polysaccharide114994004

Lactitol    O
also    O
promotes    O
colon    O
health    O
as    O
a    O
prebiotic    B-Polysaccharide114994004
.    O

Prebiotic    B-Polysaccharide114994004
(nutrition)    I-Polysaccharide114994004

They    O
have    O
some    O
utility    O
as    O
a    O
prebiotic    B-Polysaccharide114994004
.    O

Sources    O
of    O
fructans    O
include    O
wheat    O
(    O
although    O
some    O
wheat    O
strains    O
such    O
as    O
spelt    O
contain    O
lower    O
amounts    O
)    O
,    O
rye    O
,    O
barley    O
,    O
onion    O
,    O
garlic    O
,    O
Jerusalem    O
and    O
globe    O
artichoke    O
,    O
asparagus    O
,    O
beetroot    O
,    O
chicory    O
,    O
dandelion    O
leaves    O
,    O
leek    O
,    O
radicchio    O
,    O
the    O
white    O
part    O
of    O
spring    O
onion    O
,    O
broccoli    O
,    O
brussels    O
sprouts    O
,    O
cabbage    O
,    O
fennel    O
and    O
prebiotic    B-Polysaccharide114994004
such    O
as    O
fructooligosaccharides    O
(    O
FOS    B-Polysaccharide114994004
)    O
,    O
oligofructose    B-Polysaccharide114994004
and    O
inulin    O
.    O

Microbiota    O
-    O
accessible    O
carbohydrates    O
(    O
MACs    O
)    O
are    O
carbohydrates    O
that    O
are    O
resistant    O
to    O
digestion    O
by    O
a    O
host    O
's    O
metabolism    O
,    O
and    O
are    O
made    O
available    O
for    O
gut    O
microbes    O
,    O
as    O
prebiotics    B-Polysaccharide114994004
,    O
to    O
ferment    O
or    O
metabolize    O
into    O
beneficial    O
compounds    O
,    O
such    O
as    O
short    O
chain    O
fatty    O
acids    O
.    O

Strain    O
8700:2    O
breaks    O
down    O
oligofructose    B-Polysaccharide114994004
and    O
inulin    O
,    O
while    O
also    O
growing    O
rapidly    O
on    O
both    O
and    O
producing    O
lactic    O
acid    O
as    O
the    O
end    O
product    O
.    O

It    O
features    O
roughly    O
1,200    O
monographs    O
,    O
including    O
food    O
-    O
grade    O
chemicals    O
,    O
processing    O
aids    O
,    O
foods    O
(    O
such    O
as    O
vegetable    O
oils    O
,    O
fructose    O
,    O
whey    O
,    O
and    O
amino    O
acids    O
)    O
,    O
flavoring    O
agents    O
,    O
vitamins    O
,    O
and    O
functional    O
food    O
ingredients    O
(    O
such    O
as    O
lycopene    O
,    O
olestra    O
,    O
and    O
short    O
chain    O
fructooligosaccharide    B-Polysaccharide114994004
)    O
.    O

Fructooligosaccharide    B-Polysaccharide114994004

Lovenox    B-Polysaccharide114994004
(    O
Sanofi    O
-    O
Aventis    O
)    O
redirects    O
to    O
"    O
enoxaparin    B-Polysaccharide114994004
"    O

(    O
Enoxaparin    B-Polysaccharide114994004
has    O
4500    O
g    O
/    O
mol    O
)    O

Similar    O
issues    O
are    O
likely    O
associated    O
with    O
the    O
use    O
of    O
enoxaparin    B-Polysaccharide114994004
(    O
a    O
LMWH    O
)    O
in    O
these    O
high    O
-    O
risk    O
individuals    O
.    O

For    O
example    O
,    O
a    O
glucose    O
polymer    O
is    O
named    O
glucan    B-Polysaccharide114994004
,    O
a    O
mannose    O
polymer    O
is    O
named    O
mannan    B-Polysaccharide114994004
,    O
and    O
a    O
galactose    O
polymer    O
is    O
named    O
galactan    B-Polysaccharide114994004
.    O

Mannan    B-Polysaccharide114994004
argues    O
that    O
replacing    O
interest    O
with    O
profit    O
and    O
loss    O
sharing    O
would    O
stimulate    O
job    O
creation    O
and    O
economic    O
vitality    O
and    O
would    O
be    O
in    O
line    O
with    O
the    O
cooperative    O
norm    O
of    O
the    O
Quran    O
.    O

This    O
mannan    B-Polysaccharide114994004
-    O
binding    O
lectin    O
(    O
MBL    O
)    O
recognizes    O
patterns    O
of    O
neutral    O
carbohydrates    O
,    O
such    O
as    O
mannose    O
and    O
N    O
-    O
acetylglucosamine    O
.    O

elephant    O
plant’    O
with    O
'    O
large    O
fruit    O
'    O
,    O
the    O
endosperm    O
of    O
the    O
nut    O
having    O
the    O
texture    O
of    O
elephant    O
ivory    O
,    O
and    O
consisting    O
of    O
large    O
,    O
thick    O
-    O
walled    O
cells    O
of    O
two    O
long    O
-    O
chain    O
polysaccharides    O
,    O
mannan    B-Polysaccharide114994004
A    O
and    O
B.    O

Glutinous    O
rice    O
(    O
"    O
Oryza    O
sativa    O
var    O
.    O
glutinosa    O
"    O
;    O
also    O
called    O
sticky    O
rice    O
,    O
sweet    O
rice    O
or    O
waxy    O
rice    O
)    O
is    O
a    O
type    O
of    O
rice    O
grown    O
mainly    O
in    O
Southeast    O
and    O
East    O
Asia    O
and    O
the    O
eastern    O
parts    O
of    O
South    O
Asia    O
,    O
which    O
has    O
opaque    O
grains    O
,    O
very    O
low    O
amylose    B-Polysaccharide114994004
content    O
,    O
and    O
is    O
especially    O
sticky    O
when    O
cooked    O
.    O

Glutinous    O
rice    O
is    O
distinguished    O
from    O
other    O
types    O
of    O
rice    O
by    O
having    O
no    O
(    O
or    O
negligible    O
amounts    O
of    O
)    O
amylose    B-Polysaccharide114994004
,    O
and    O
high    O
amounts    O
of    O
amylopectin    B-Polysaccharide114994004
(    O
the    O
two    O
components    O
of    O
starch    O
)    O
.    O

It    O
is    O
most    O
commonly    O
produced    O
by    O
the    O
digestive    O
enzyme    O
alpha    O
-    O
amylase    O
(    O
a    O
common    O
enzyme    O
in    O
human    O
saliva    O
)    O
on    O
amylose    B-Polysaccharide114994004
in    O
starch    O
.    O

Floridean    O
starch    O
is    O
often    O
described    O
in    O
contrast    O
to    O
starch    O
(    O
a    O
mixture    O
of    O
amylopectin    B-Polysaccharide114994004
and    O
amylose    B-Polysaccharide114994004
)    O
and    O
glycogen    O
:    O

Historically    O
,    O
floridean    O
starch    O
has    O
been    O
described    O
as    O
lacking    O
amylose    B-Polysaccharide114994004
.    O

Conventionally    O
,    O
kibi    O
dango    O
or    O
"    O
kibi    O
mochi    O
"    O
uses    O
the    O
sticky    O
variety    O
proso    O
millet    O
known    O
as    O
"    O
mochi    O
kibi    O
"    O
,    O
rather    O
thant    O
the    O
regular    O
(    O
amylose    B-Polysaccharide114994004
-    O
rich    O
)    O
millet    O
used    O
for    O
creating    O
sweets    O
.    O

When    O
cooked    O
,    O
the    O
rice    O
does    O
not    O
turn    O
sticky    O
,    O
possesses    O
minimum    O
breadth    O
-    O
wise    O
expansion    O
,    O
and    O
is    O
aromatic    O
with    O
intermediate    O
alkali    O
-    O
spreading    O
value    O
and    O
amylose    B-Polysaccharide114994004
content    O
.    O

The    O
fusion    O
protein    O
binds    O
to    O
amylose    B-Polysaccharide114994004
columns    O
while    O
all    O
other    O
proteins    O
flow    O
through    O
.    O

In    O
2007    O
in    O
Bernin    O
,    O
France    O
,    O
Karam    O
founded    O
the    O
LEYLA    O
Charity    O
,    O
named    O
for    O
his    O
mother    O
who    O
died    O
in    O
1995    O
,    O
at    O
age    O
48    O
,    O
from    O
amylose    B-Polysaccharide114994004
,    O
a    O
rare    O
and    O
orphan    O
disease    O
.    O

OVDs    O
contain    O
one    O
or    O
more    O
of    O
the    O
following    O
substances    O
in    O
varying    O
concentrations    O
:    O
sodium    B-Polysaccharide114994004
hyaluronate    I-Polysaccharide114994004
,    O
chondroitin    B-Polysaccharide114994004
sulfate    I-Polysaccharide114994004
,    O
or    O
hydroxypropyl    B-Polysaccharide114994004
methylcellulose    I-Polysaccharide114994004
.    O

Other    O
ingredients    O
include    O
dicalcium    O
phosphate    O
,    O
microcrystalline    O
cellulose    O
,    O
croscarmellose    O
sodium    O
,    O
stearic    O
acid    O
,    O
film    O
coating    O
(    O
dextrin    O
)    O
,    O
titanium    O
dioxide    O
,    O
hydroxypropylmethyl    B-Polysaccharide114994004
cellulose    I-Polysaccharide114994004
,    O
Brilliant    O
Blue    O
FCF    O
,    O
aluminum    O
lake    O
,    O
Macrogol    O
/    O
PEG    O
8000    O
,    O
dextrose    O
monohydrate    O
,    O
lecithin    O
,    O
maltodextrin    B-Polysaccharide114994004
,    O
Macrogol    O
/    O
PEG    O
400    O
,    O
magnesium    O
stearate    O
,    O
and    O
silica    O
.    O

Valtrex    O
is    O
offered    O
in    O
250    O
mg    O
,    O
500    O
mg    O
,    O
and    O
1    O
gram    O
tablets    O
,    O
the    O
active    O
ingredient    O
being    O
valacyclovir    O
hydrochloride    O
,    O
with    O
the    O
inactive    O
ingredients    O
carnauba    O
wax    O
,    O
colloidal    O
silicon    O
dioxide    O
,    O
crospovidone    O
,    O
FD&C    O
Blue    O
No    O
.    O
2    O
Lake    O
,    O
hypromellose    B-Polysaccharide114994004
,    O
magnesium    O
stearate    O
,    O
microcrystalline    B-Polysaccharide114994004
cellulose    I-Polysaccharide114994004
,    O
polyethylene    O
glycol    O
,    O
polysorbate    O
80    O
,    O
povidone    O
,    O
and    O
titanium    O
dioxide    O
.    O

α-Cyclodextrin    B-Polysaccharide114994004

For    O
example    O
,    O
a    O
glucose    O
polymer    O
is    O
named    O
glucan    B-Polysaccharide114994004
,    O
a    O
mannose    O
polymer    O
is    O
named    O
mannan    B-Polysaccharide114994004
,    O
and    O
a    O
galactose    O
polymer    O
is    O
named    O
galactan    B-Polysaccharide114994004
.    O

The    O
topical    O
application    O
of    O
a    O
cream    O
containing    O
a    O
Heparinoid    B-Polysaccharide114994004
is    O
often    O
advised    O
to    O
clear    O
the    O
clot    O
.    O

He    O
showed    O
that    O
the    O
attachment    O
of    O
organisms    O
must    O
be    O
preceded    O
by    O
the    O
adsorption    O
of    O
organic    O
compounds    O
now    O
referred    O
to    O
as    O
extracellular    B-Polysaccharide114994004
polymeric    I-Polysaccharide114994004
substances    I-Polysaccharide114994004
.    O

Extracellular    B-Polysaccharide114994004
polymeric    I-Polysaccharide114994004
substance    I-Polysaccharide114994004
,    O
or    O
exopolysaccharide    O
,    O
sticky    O
organic    O
matter    O
produced    O
by    O
microorganisms    O

Medically    O
,    O
Cellulase    O
is    O
used    O
as    O
a    O
treatment    O
for    O
phytobezoars    O
,    O
a    O
form    O
of    O
cellulose    O
bezoar    O
found    O
in    O
the    O
human    O
stomach    O
,    O
and    O
it    O
has    O
exhibited    O
efficacy    O
in    O
degrading    O
polymicrobial    O
bacterial    O
biofilms    O
by    O
hydrolyzing    O
the    O
β(1    O
-    O
4    O
)    O
glycosidic    O
linkages    O
within    O
the    O
structural    O
,    O
matrix    O
exopolysaccharides    O
of    O
the    O
extracellular    B-Polysaccharide114994004
polymeric    I-Polysaccharide114994004
substance    I-Polysaccharide114994004
(    O
EPS    O
)    O
.    O

Galactosaminogalactan    O
(    O
commonly    O
abbreviated    O
as    O
GAG    O
or    O
GG    O
)    O
,    O
is    O
an    O
exopolysaccharide    B-Polysaccharide114994004
composed    O
of    O
galactose    O
and    O
N    O
-    O
acetylgalactosamine    O
(    O
GalNAc    O
)    O
.    O

The    O
accessory    O
genome    O
is    O
overtaken    O
by    O
genes    O
encoding    O
carbohydrate    O
transport    O
and    O
metabolism    O
,    O
extracellular    B-Polysaccharide114994004
polysaccharides    I-Polysaccharide114994004
,    O
biosynthesis    O
,    O
bacteriocin    O
production    O
,    O
pili    O
production    O
,    O
the    O
cassystem    O
,    O
the    O
clustered    O
regularly    O
interspaced    O
short    O
palindromic    O
repeat    O
(    O
CRISPR    O
)    O
loci    O
,    O
and    O
more    O
than    O
100    O
transporter    O
functions    O
and    O
mobile    O
genetic    O
elements    O
such    O
as    O
phages    O
,    O
plasmid    O
genes    O
,    O
and    O
transposons    O
.    O

The    O
opportunistic    O
pathogen    O
"    O
Pseudomonas    O
aeruginosa    O
"    O
uses    O
quorum    O
sensing    O
to    O
coordinate    O
the    O
formation    O
of    O
biofilms    O
,    O
swarming    O
motility    O
,    O
exopolysaccharide    B-Polysaccharide114994004
production    O
,    O
virulence    O
,    O
and    O
cell    O
aggregation    O
.    O

Arthrobacter    O
viscosus    O
"    O
produces    O
exopolysaccharide    B-Polysaccharide114994004
.    O

Capsulan    B-Polysaccharide114994004
is    O
the    O
exopolysaccharide    B-Polysaccharide114994004
which    O
makes    O
up    O
the    O
thick    O
capsule    O
surrounding    O
the    O
unicellular    O
alga    O
"    O
Prasinococcus    O
capsulatus    O
"    O
.    O

Unfractionated    O
heparin    O
,    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
,    O
warfarin    O
(    O
not    O
to    O
be    O
used    O
during    O
pregnancy    O
)    O
and    O
aspirin    O
remain    O
the    O
basis    O
of    O
antithrombotic    O
treatment    O
and    O
prophylaxis    O
both    O
before    O
and    O
during    O
pregnancy    O
.    O

Rather    O
,    O
women    O
who    O
are    O
on    O
chronic    O
anticoagulation    O
may    O
be    O
given    O
the    O
option    O
of    O
conversion    O
to    O
either    O
unfractionated    O
heparin    O
or    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
(    O
LMWH    O
)    O
,    O
such    O
as    O
tinzaparin    B-Polysaccharide114994004
,    O
prior    O
to    O
a    O
planned    O
conception    O
.    O

A    O
dose    O
of    O
1    O
mg    O
protamine    O
/    O
100    O
IU    O
LMWH    O
reverses    O
90%    O
of    O
its    O
anti    O
-    O
IIa    O
and    O
60%    O
of    O
anti-Xa    B-Polysaccharide114994004
activity    I-Polysaccharide114994004
,    O
but    O
the    O
clinical    O
effect    O
of    O
the    O
residual    O
anti    O
-    O
Xa    O
activity    O
is    O
not    O
known    O
.    O

Initial    O
treatment    O
generally    O
consists    O
of    O
intravenous    O
fluids    O
to    O
manage    O
dehydration    O
,    O
intravenous    O
insulin    O
in    O
those    O
with    O
significant    O
ketones    O
,    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
to    O
decrease    O
the    O
risk    O
of    O
blood    O
clotting    O
,    O
and    O
antibiotics    O
among    O
those    O
in    O
whom    O
there    O
is    O
concerns    O
of    O
infection    O
.    O

Nadroparin    B-Polysaccharide114994004
(    O
trade    O
name    O
,    O
Fraxiparine    O
or    O
Fraxodi    O
)    O
is    O
an    O
anticoagulant    O
belonging    O
to    O
a    O
class    O
of    O
drugs    O
called    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
(    O
LMWHs    O
)    O
.    O

Clinical    O
trials    O
have    O
shown    O
promise    O
for    O
these    O
compounds    O
as    O
substitutes    O
for    O
the    O
currently    O
administered    O
vitamin    O
K    O
antagonists    O
or    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
.    O

Clinical    O
practice    O
guidelines    O
now    O
recommend    O
heparin    O
or    O
low    B-Polysaccharide114994004
molecular    I-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
in    O
the    O
initial    O
treatment    O
,    O
followed    O
by    O
warfarin    O
,    O
provided    O
there    O
are    O
no    O
other    O
bleeding    O
risks    O
that    O
would    O
make    O
these    O
treatments    O
unsuitable    O
.    O

COX    O
inhibitors    O
(    O
namely    O
aspirin    O
)    O
,    O
warfarin    O
,    O
direct    O
Xa    O
inhibitors    O
,    O
direct    O
thrombin    O
inhibitors    O
,    O
heparin    O
,    O
low-molecular    B-Polysaccharide114994004
weight    I-Polysaccharide114994004
heparin    I-Polysaccharide114994004
,    O
antibodies    O
(    O
e.g.    O
,    O
abciximab    O
)    O
,    O
and    O
a    O
few    O
others    O
are    O
used    O
for    O
anticoagulation    O
therapy    O
.    O

Fucoidan    B-Polysaccharide114994004
is    O
a    O
sulfated    O
polysaccharide    O
(    O
MW    O
:    O
average    O
20,000    O
)    O
found    O
mainly    O
in    O
various    O
species    O
of    O
brown    O
algae    O
and    O
brown    O
seaweed    O
such    O
as    O
mozuku    O
,    O
kombu    O
,    O
bladderwrack    O
,    O
wakame    O
,    O
and    O
hijiki    O
(    O
variant    O
forms    O
of    O
fucoidan    O
have    O
also    O
been    O
found    O
in    O
animal    O
species    O
,    O
including    O
the    O
sea    O
cucumber    O
)    O
.    O

They    O
have    O
cellulose    O
walls    O
with    O
alginic    O
acid    O
and    O
also    O
contain    O
the    O
polysaccharide    O
fucoidan    B-Polysaccharide114994004
in    O
the    O
amorphous    O
sections    O
of    O
their    O
cell    O
walls    O
.    O

for    O
example    O
,    O
microcristalline    O
cellulose    O
is    O
converted    O
to    O
15    O
and    O
22%    O
after    O
24h    O
and    O
66h    O
,    O
respectively    O
,    O
whereas    O
the    O
more    O
reactive    O
xylan    B-Polysaccharide114994004
is    O
converted    O
to    O
88%    O
and    O
94%    O
respectively    O
.    O

Glucose    O
monomers    O
can    O
polymerize    O
to    O
form    O
starches    O
,    O
glycogen    O
or    O
cellulose    O
;    O
xylose    O
monomers    O
can    O
polymerise    O
to    O
form    O
xylan    B-Polysaccharide114994004
.    O

According    O
to    O
NCBI    O
,    O
this    O
domain    O
is    O
in    O
the    O
family    O
of    O
proteins    O
expected    O
play    O
a    O
role    O
in    O
xylan    B-Polysaccharide114994004
biosynthesis    O
in    O
plant    O
cell    O
walls    O
,    O
but    O
its    O
exact    O
role    O
in    O
the    O
synthesis    O
pathway    O
is    O
unknown    O
.    O

An    O
example    O
of    O
this    O
is    O
that    O
secondary    O
wall    O
in    O
wood    O
contain    O
polysaccharides    O
called    O
xylan    B-Polysaccharide114994004
,    O
whereas    O
the    O
primary    O
wall    O
contains    O
the    O
polysaccharide    O
xyloglucan    B-Polysaccharide114994004
.    O

Grown    O
in    O
axenic    O
culture    O
in    O
the    O
laboratory    O
,    O
the    O
fungus    O
mycelium    O
has    O
been    O
shown    O
to    O
degrade    O
(    O
in    O
addition    O
to    O
lignin    O
and    O
cellulose    O
)    O
hemicellulose    B-Polysaccharide114994004
,    O
protein    O
,    O
soluble    O
carbohydrates    O
,    O
and    O
purified    O
xylan    B-Polysaccharide114994004
and    O
pectin    O
using    O
enzymes    O
such    O
as    O
polyphenol    O
oxidases    O
,    O
cellulases    O
,    O
and    O
catalase    O
.    O


